

Regorafenib monotherapy for previously treated metastatic colorectal cancer: an international, multicentre, randomised, placebo-controlled trial

Lancet, The

381, 303-312

DOI: [10.1016/s0140-6736\(12\)61900-x](https://doi.org/10.1016/s0140-6736(12)61900-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Systemic chemotherapy for hepatic colorectal cancer. , 2012, , 1434-1443.e3.		0
2	Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept. <i>Biologics in Therapy</i> , 2013, 3, 25-33.	1.8	8
3	Regorafenib for metastatic colorectal cancer. <i>Lancet, The</i> , 2013, 381, 1537.	6.3	15
4	Regorafenib: from bench to bedside in colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 243-248.	1.3	4
5	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013, 49, 3412-3419.	1.3	218
6	Regorafenib (BAY 73â€“4506): Stromal and Oncogenic Multikinase Inhibitor with Potential Activity in Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2013, 15, 91-97.	1.8	12
7	SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 996-1003.	1.2	20
8	The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 230-241.	1.0	2
9	Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 213-222.	1.0	1
10	Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. <i>Investigational New Drugs</i> , 2013, 31, 1078-1086.	1.2	86
11	Editorâ€™s Suggested Readings in Interventional Oncology. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1165-1166.	0.2	1
12	Axitinib and/or bevacizumab with modified FOLFOXâ€“6 as firstâ€“line therapy for metastatic colorectal cancer: A randomized phase 2 study. <i>Cancer</i> , 2013, 119, 2555-2563.	2.0	39
13	United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. <i>Current Problems in Cancer</i> , 2013, 37, 110-144.	1.0	50
14	A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2013, 109, 1725-1734.	2.9	38
15	Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use. <i>Drugs</i> , 2013, 73, 2003-2015.	4.9	48
16	A phase I study of sorafenib, oxaliplatin and 2âˆ“days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. <i>Investigational New Drugs</i> , 2013, 31, 943-948.	1.2	9
17	Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 723-761.	2.7	52
18	To Market, To Marketâ€“2012. <i>Annual Reports in Medicinal Chemistry</i> , 2013, 48, 471-546.	0.5	14

#	ARTICLE	IF	CITATIONS
19	How Do We Make Choices in Salvage Therapy: Panitumumab, Cetuximab, or Regorafenib?. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 326-330.	1.0	0
20	Viral Vector Vaccines To Treat Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 398-405.	1.0	2
21	Regorafenib for Gastrointestinal Malignancies. <i>BioDrugs</i> , 2013, 27, 213-224.	2.2	37
22	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2203-2220.	0.9	4
23	Bevacizumab for the treatment of glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 937-949.	1.4	21
24	Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?. <i>Cancer Management and Research</i> , 2013, 5, 103.	0.9	40
25	Revisiting landmark trials and identifying new therapies. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 71-72.	12.5	6
26	Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study. <i>Clinical Colorectal Cancer</i> , 2013, 12, 239-247.	1.0	28
27	How we treat metastatic colon cancer in older adults. <i>Journal of Geriatric Oncology</i> , 2013, 4, 295-301.	0.5	11
28	Regorafenib for metastatic colorectal cancer. <i>Lancet, The</i> , 2013, 381, 1536-1537.	6.3	7
29	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€™Part II. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1167-1188.	0.2	26
30	Regorafenib for metastatic colorectal cancer. <i>Lancet, The</i> , 2013, 381, 1537-1538.	6.3	3
31	Regorafenib for metastatic colorectal cancer â€™ Authors' reply. <i>Lancet, The</i> , 2013, 381, 1538-1539.	6.3	9
32	Panitumumab Rechallenge in Chemorefractory Patients with Metastatic Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 456-459.	0.6	11
33	Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives. <i>Cancer Treatment Reviews</i> , 2013, 39, 908-924.	3.4	37
34	Role of targeted agents in metastatic colorectal cancer. <i>Targeted Oncology</i> , 2013, 8, 83-96.	1.7	58
35	Targeting angiopoietin-2 signaling in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 813-825.	1.9	33
36	Emerging tyrosine kinase inhibitors for esophageal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 219-230.	1.0	9

#	ARTICLE	IF	CITATIONS
37	Panitumumab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 781-793.	1.1	5
38	AERIO News in brief. Oncologie, 2013, 15, 271-274.	0.2	0
39	Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials. Annals of Oncology, 2013, 24, 2943-2952.	0.6	46
40	Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management. Current Treatment Options in Oncology, 2013, 14, 389-404.	1.3	20
41	Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemotherapy and Pharmacology, 2013, 72, 869-877.	1.1	14
42	AACR Cancer Progress Report 2013. Clinical Cancer Research, 2013, 19, S1-S98.	3.2	55
45	Regorafenib use as a possible cause of intestinal perforation. Acta Oncologica, 2013, 52, 1789-1790.	0.8	7
46	Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Annals of Oncology, 2013, 24, 1560-1567.	0.6	79
47	Regorafenib, the CORRECT way forward or just another GRIDlock?. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 1-1.	8.2	3
48	Regorafenib, the CORRECT way forward or just another GRIDlock?. Nature Reviews Clinical Oncology, 2013, 10, 1-1.	12.5	4
49	Angiopoietins and Non-Vascular Endothelial Growth Factor Antiangiogenic Targets in Advanced Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass ), 2013, 19, 307-310.	1.0	5
50	Ziv-aflibercept in metastatic colorectal cancer. Biologics: Targets and Therapy, 2013, 8, 13.	3.0	30
51	New developments in management of gastrointestinal stromal tumors: regorafenib, the new player in the team. Gastrointestinal Cancer: Targets and Therapy, 2013, , 1.	5.5	3
52	Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type <i>KRAS</i> . Cancer Science, 2013, 104, 473-480.	1.7	6
53	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews, 2013, 65, 1351-1395.	7.1	33
54	Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clinical Cancer Research, 2013, 19, 2541-2550.	3.2	72
55	Recent advances in oral anticancer agents for colon cancer. Future Oncology, 2013, 9, 1893-1908.	1.1	3
56	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. Journal of Clinical Oncology, 2013, 31, 2477-2484.	0.8	122

#	ARTICLE	IF	CITATIONS
57	The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 381-395.	1.4	33
58	Regorafenib. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1685-1696.	0.9	45
59	HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy?. <i>British Journal of Cancer</i> , 2013, 108, 477-478.	2.9	3
60	Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 459-473.	1.4	27
61	Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2265-2272.	3.2	96
62	Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy. <i>Cancer Research</i> , 2013, 73, 1649-1657.	0.4	177
63	Regorafenib: carving a niche in the crowded therapeutic landscape. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 385-393.	1.1	4
64	Sequencing of Treatment in Advanced Unresectable Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-28-S-37.	2.3	3
65	Emerging Treatments in Recurrent and Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-18-S-27.	2.3	9
66	Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2013, 2, 411-417.	0.8	1
67	Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2013, 8, e62264.	1.1	21
68	Systemic Therapy for Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 649-652.	2.3	9
70	Results in Liver Metastatic Colorectal Cancer. <i>Medical Radiology</i> , 2013, , 141-149.	0.0	1
71	Critical appraisal of the use of regorafenib in the management of colorectal cancer. <i>Cancer Management and Research</i> , 2013, 5, 49.	0.9	5
72	Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). <i>Cancer Management and Research</i> , 2013, 5, 377.	0.9	10
73	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. <i>PLoS ONE</i> , 2013, 8, e66774.	1.1	64
74	Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-Enhanced Computed Tomography with Immunohistochemical Validation. <i>PLoS ONE</i> , 2013, 8, e76009.	1.1	26
75	Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine. <i>PLoS ONE</i> , 2013, 8, e81628.	1.1	86

#	ARTICLE	IF	CITATIONS
76	Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. <i>Cancer Management and Research</i> , 2014, 6, 93.	0.9	18
77	Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e90135.	1.1	63
78	Colorectal cancer in Chinese patients: current and emerging treatment options. <i>OncoTargets and Therapy</i> , 2014, 7, 1817.	1.0	29
79	Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. <i>Current Oncology</i> , 2014, 21, 129.	0.9	58
80	Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. <i>OncoTargets and Therapy</i> , 2014, 7, 501.	1.0	6
81	FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. <i>OncoTargets and Therapy</i> , 2014, 7, 2143.	1.0	8
82	Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 1121-1127.	0.9	39
83	Advances and new perspectives in the treatment of metastatic colon cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2014, 6, 211.	0.8	25
84	Obstacles to Affordable Cancer Treatments. <i>North Carolina Medical Journal</i> , 2014, 75, 257-260.	0.1	6
85	Targeting metastatic colorectal cancer &ndash; present and emerging treatment options. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 137.	0.4	14
86	Management of locally advanced and metastatic colon cancer in elderly patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 1910.	1.4	17
87	New Strategies to Enhance the Efficacy of Surgical Treatment for Colorectal Liver Metastasis. , 2014, , .		1
88	90Y Radioembolization. <i>Oncology Issues</i> , 2014, 29, 46-52.	0.0	0
89	Sequencing of treatment in metastatic colorectal cancer: Where to fit the target. <i>World Journal of Gastroenterology</i> , 2014, 20, 1993.	1.4	23
90	Colorectal Cancer: All Hands on Deck. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 83-89.	1.8	9
92	Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care. <i>Oncologist</i> , 2014, 19, 669-680.	1.9	61
93	Anti-angiogenic agent ramucirumab: meaningful or marginal?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 367-379.	1.1	12
94	The preclinical development of regorafenib for the treatment of colorectal cancer. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 1087-1101.	2.5	27

#	ARTICLE	IF	CITATIONS
95	Regorafenib in metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 255-265.	1.1	20
96	Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. <i>Future Oncology</i> , 2014, 10, 285-304.	1.1	13
97	An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014, 32, 1258-1268.	1.2	11
98	Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 942-953.	1.2	28
99	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 477-486.	1.0	0
100	Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 222-228.	1.4	19
101	Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis. <i>Tumor Biology</i> , 2014, 35, 10715-10722.	0.8	20
102	Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis. <i>Clinical Cancer Research</i> , 2014, 20, 3472-3484.	3.2	93
103	Successes and Limitations of Targeted Cancer Therapy in Colon Cancer. <i>Progress in Tumor Research</i> , 2014, 41, 36-50.	0.1	18
104	Case histories in unresectable liver-dominant metastatic colorectal cancer. <i>Future Oncology</i> , 2014, 10, 41-47.	1.1	1
105	Multi-target angiokinase inhibitors to fight resistance. <i>Cell Cycle</i> , 2014, 13, 2649-2650.	1.3	4
106	Role of aflibercept in the treatment of advanced colorectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 27-40.	0.8	0
107	Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-13.	0.7	44
108	Immune Escape Mechanisms in Colorectal Cancer Pathogenesis and Liver Metastasis. <i>Journal of Immunology Research</i> , 2014, 2014, 1-11.	0.9	86
109	Moguntinonesâ€”New Selective Inhibitors for the Treatment of Human Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1399-1409.	1.9	5
110	The development of anti-angiogenic heparan sulfate oligosaccharides. <i>Biochemical Society Transactions</i> , 2014, 42, 1596-1600.	1.6	6
111	Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1319-1332.	1.4	12
112	Genomic landscape of metastatic colorectal cancer. <i>Nature Communications</i> , 2014, 5, 5457.	5.8	61

#	ARTICLE	IF	CITATIONS
113	Targeted therapy in gastrointestinal malignancies. <i>Journal of Carcinogenesis</i> , 2014, 13, 4.	2.5	7
114	Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	18
115	Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. <i>Hepatic Oncology</i> , 2014, 1, 331-345.	4.2	0
116	Cost of selective internal radiation therapy versus other modalities. <i>Future Oncology</i> , 2014, 10, 101-104.	1.1	0
118	Metronomic Chemotherapy. , 2014, , .		3
119	DNA synthesis inhibitors for the treatment of gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2361-2372.	0.9	4
120	Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1497-1505.	0.8	9
121	FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer. <i>Oncology</i> , 2014, 87, 148-158.	0.9	15
122	Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 748-762.	1.1	81
123	Clinical experience with ramucirumab: outcomes in breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1351-1360.	1.4	5
124	Chemotherapy-induced peripheral neurotoxicity (<scp>CIPN</scp>): what we need and what we know. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 66-76.	1.4	48
125	Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. <i>British Journal of Cancer</i> , 2014, 110, 1148-1154.	2.9	49
126	Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer. <i>British Journal of Cancer</i> , 2014, 111, 265-271.	2.9	19
127	Regorafenib for treatment of advanced gastrointestinal stromal tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 549-558.	0.9	19
128	Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 20-37.	1.4	28
130	Biomarkers in Metastatic Colorectal Cancer. , 2014, , 1-25.		0
131	Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1636-1644.	1.9	56
132	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1477-1493.	1.1	12



#	ARTICLE	IF	CITATIONS
133	Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. <i>Future Medicinal Chemistry</i> , 2014, 6, 1771-1789.	1.1	13
134	Myxoid variant of adrenocortical carcinoma: a report of two illustrative cases and a brief review of the literature. <i>Pathology</i> , 2014, 46, 83-85.	0.3	6
135	Osseous metaplasia in polypoid rectal mucosal prolapse. <i>Pathology</i> , 2014, 46, 80-83.	0.3	1
136	Bilateral, multicentric low-grade adenosquamous carcinomas of the breast, each arising within a separate radial scar/complex sclerosing lesion. <i>Pathology</i> , 2014, 46, 85-88.	0.3	11
137	Detection of hepatitis B virus DNA in serum is rare in the absence of hepatitis B surface antigen: impacts for detection and monitoring of chronic hepatitis B. <i>Pathology</i> , 2014, 46, 69-71.	0.3	0
138	BRAF V600E mutation specific immunohistochemistry with clone VE1 is not reliable in pituitary adenomas. <i>Pathology</i> , 2014, 46, 79-80.	0.3	7
139	A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia. <i>Pathology</i> , 2014, 46, 73-75.	0.3	9
140	Optimal duration of systemic treatment in metastatic colorectal cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 448-453.	1.1	9
141	Plasmablastic lymphoma presenting as a colonic stricture in Crohn's disease. <i>Pathology</i> , 2014, 46, 77-79.	0.3	7
142	Ras in digestive oncology. <i>Current Opinion in Oncology</i> , 2014, 26, 454-461.	1.1	11
143	An update on the safety and efficacy of regorafenib in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1607-1614.	1.5	10
144	New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing. <i>Oncologist</i> , 2014, 19, 235-242.	1.9	371
145	E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts. <i>Neoplasia</i> , 2014, 16, 972-981.	2.3	20
146	Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 1225.	1.2	263
147	Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. <i>Clinical Sarcoma Research</i> , 2014, 4, 17.	2.3	16
148	Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement. <i>Future Oncology</i> , 2014, 10, 2643-2657.	1.1	6
149	Chronic myeloid leukaemia masquerading as primary myelofibrosis. <i>Pathology</i> , 2014, 46, 75-77.	0.3	0
150	Activity of ceftaroline against community associated and healthcare associated methicillin resistant <i>Staphylococcus aureus</i> . <i>Pathology</i> , 2014, 46, 71-73.	0.3	1

#	ARTICLE	IF	CITATIONS
151	Pilot Study of Angiogenic Response to Yttrium-90 Radioembolization with Resin Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 297-306.e1.	0.2	29
152	Personalizing Therapy for Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 139-144.	2.4	25
153	What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 83-106.	2.0	30
154	Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 787-794.	0.6	156
155	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. <i>International Journal of Cancer</i> , 2014, 134, 2513-2522.	2.3	288
156	Treatment-related mortality with aflibercept in cancer patients: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 461-467.	0.8	11
157	Dysphonia induced by anti-angiogenic compounds. <i>Investigational New Drugs</i> , 2014, 32, 774-782.	1.2	19
158	Fibroblast Growth Factor Receptor-2 Ilc as a Novel Molecular Target in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 20-26.	1.0	0
159	A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 537-547.	1.2	85
160	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. <i>Angiogenesis</i> , 2014, 17, 471-494.	3.7	626
161	Prevention and management of adverse events related to regorafenib. <i>Supportive Care in Cancer</i> , 2014, 22, 837-846.	1.0	54
163	Regorafenib (BAY 734506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 1487-1496.	2.3	103
164	Discrete Improvement in Racial Disparity in Survival among Patients with Stage IV Colorectal Cancer: a 21-Year Population-Based Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1194-1204.	0.9	18
165	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2014, , .	1.8	4
166	The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. <i>Angiogenesis</i> , 2014, 17, 805-821.	3.7	21
167	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014, 135, 763-773.	2.3	43
168	Molecular therapy of colorectal cancer: Progress and future directions. <i>International Journal of Cancer</i> , 2015, 136, 493-502.	2.3	53
169	The ErbB/HER family of protein-tyrosine kinases and cancer. <i>Pharmacological Research</i> , 2014, 79, 34-74.	3.1	1,028

#	ARTICLE	IF	CITATIONS
170	Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?. Current Oncology Reports, 2014, 16, 363.	1.8	9
171	Regorafenib: A Review of Its Use in Previously Treated Patients with Progressive Metastatic Colorectal Cancer. Drugs and Aging, 2014, 31, 67-78.	1.3	21
172	Methods of overcoming treatment resistance in colorectal cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 217-230.	2.0	58
173	Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2014, 70, 225-231.	0.8	53
174	Targeted therapy-induced diarrhea: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 165-179.	2.0	47
175	Towards improved drugs, combinations and patient selection. Nature Reviews Clinical Oncology, 2014, 11, 79-80.	12.5	49
176	Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 2014, 26, 605-622.	7.7	1,184
177	Ziv-aflibercept (Zaltrap) for the Treatment of Metastatic Colorectal Cancer. Annals of Pharmacotherapy, 2014, 48, 93-98.	0.9	16
178	Regorafenib-induced hyperammonemic encephalopathy. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 446-448.	0.7	15
180	New Targets and New Drug Development in Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 288-295.	1.0	1
181	Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 335.	0.4	33
182	Navigating later lines of treatment for advanced colorectal cancer – Optimizing targeted biological therapies to improve outcomes. Cancer Treatment Reviews, 2014, 40, 1171-1181.	3.4	18
183	The role of targeted therapy for gastrointestinal tumors. Expert Review of Gastroenterology and Hepatology, 2014, 8, 875-885.	1.4	27
184	Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii1-iii9.	0.6	910
185	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. British Journal of Clinical Pharmacology, 2014, 77, 929-938.	1.1	65
186	Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data. Oncologist, 2014, 19, 1156-1168.	1.9	90
187	Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients. Journal of Clinical Oncology, 2014, 32, 1620-1629.	0.8	60
188	The multifaceted activity of VEGF in angiogenesis – Implications for therapy responses. Cytokine and Growth Factor Reviews, 2014, 25, 473-482.	3.2	120

#	ARTICLE	IF	CITATIONS
189	Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 260-263.	0.8	19
190	Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 194-207.	2.0	52
191	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. <i>Journal of Clinical Oncology</i> , 2014, 32, 1521-1530.	0.8	36
192	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280.	0.8	354
193	Advances in the management of colorectal cancer: from biology to treatment. <i>International Journal of Colorectal Disease</i> , 2014, 29, 1031-1042.	1.0	75
194	The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 934-941.	3.4	16
195	Progression-free survival as an end-point in solid tumours " Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308.	1.3	32
196	New advances in local therapy for colorectal cancer metastases to the liver. <i>Colorectal Cancer</i> , 2014, 3, 183-193.	0.8	0
197	Targeted Therapy in Older Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 2635-2646.	0.8	36
198	How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 743-748.	1.4	15
200	Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. <i>BMC Cancer</i> , 2014, 14, 510.	1.1	23
201	Whole genome sequencing reveals potential targets for therapy in patients with refractory KRASmutated metastatic colorectal cancer. <i>BMC Medical Genomics</i> , 2014, 7, 36.	0.7	18
202	Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. <i>Vascular Cell</i> , 2014, 6, 18.	0.2	349
203	A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 479-486.	1.1	14
205	Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1861-1869.	3.3	80
206	A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 117-123.	1.1	9
207	Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1-13.	1.1	16
208	Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 447-455.	1.1	4

#	ARTICLE	IF	CITATIONS
209	Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics. <i>Oncologie</i> , 2014, 16, 267-276.	0.2	2
210	Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. <i>Investigational New Drugs</i> , 2014, 32, 535-541.	1.2	30
211	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014, 25, 404-408.	0.6	67
212	Anti-Prokineticin1 (PROK1) Monoclonal Antibody Suppresses Angiogenesis and Tumor Growth in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 665-671.	0.7	9
213	Clinical End Points and Relevant Clinical Benefits in Advanced Colorectal Cancer Trials. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 254-262.	1.0	0
214	Endoglin for Targeted Cancer Treatment. <i>Current Oncology Reports</i> , 2014, 16, 365.	1.8	83
215	Afliberceptâ€™a Decoy VEGF Receptor. <i>Current Oncology Reports</i> , 2014, 16, 368.	1.8	56
216	A Case Reportâ€™Treatment of Metastatic Colorectal Cancer in a Patient on Hemodialysis. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 161-165.	0.6	3
217	The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials. <i>Tumor Biology</i> , 2014, 35, 7675-7683.	0.8	10
218	Colon Cancer in Older Adults: A Primer for Geriatricians. <i>Current Geriatrics Reports</i> , 2014, 3, 190-199.	1.1	0
219	Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1051-1061.	1.1	3
220	Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 156-163.e2.	1.0	23
222	Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinicianâ€™s perspective. <i>Cancer Treatment Reviews</i> , 2014, 40, 1065-1072.	3.4	15
223	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. <i>Cancer</i> , 2014, 120, 2164-2173.	2.0	27
224	Refining the Chemotherapy Approach for Older Patients With Colon Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2570-2580.	0.8	54
225	The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. <i>British Journal of Cancer</i> , 2014, 111, 1122-1131.	2.9	28
226	The Emerging Role of QSOX1 in Cancer. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 485-496.	2.5	45
227	Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 9-34.	2.0	27

#	ARTICLE	IF	CITATIONS
228	Sequencing of Antiangiogenic Agents in the Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 135-144.	1.0	27
229	Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond. <i>Seminars in Oncology</i> , 2014, 41, 235-251.	0.8	129
230	Options for metastatic colorectal cancer beyond the second line of treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 105-112.	0.4	42
231	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 241-250.	0.9	25
232	Metabolic effects of antiangiogenic drugs in tumors: Therapeutic implications. <i>Biochemical Pharmacology</i> , 2014, 89, 162-170.	2.0	20
233	BRAF inhibitors: From the laboratory to clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 220-232.	2.0	35
234	Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1063-1073.	1.1	36
235	Molecular Mechanisms of Angiogenesis. , 2014, , .		5
236	A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/â' targeted therapy. <i>Cancer Treatment Reviews</i> , 2014, 40, 701-715.	3.4	64
237	Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 218-226.	2.0	11
238	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 496-505.	1.3	26
239	Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. <i>Progress in Lipid Research</i> , 2014, 53, 108-123.	5.3	133
240	Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. <i>Investigational New Drugs</i> , 2014, 32, 104-112.	1.2	48
241	Management of colorectal cancer. <i>F1000prime Reports</i> , 2014, 6, 108.	5.9	86
243	SIR-Spheres<sup>Â®</sup> radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. <i>Colorectal Cancer</i> , 2014, 3, 331-343.	0.8	0
244	Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases. <i>Hepatic Oncology</i> , 2014, 1, 81-94.	4.2	9
246	Evidence-based integration of selective internal radiation therapy in the management of colorectal liver metastases. <i>Future Oncology</i> , 2014, 10, 33-36.	1.1	0
247	Regorafenib as a new standard of care in advanced colorectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 417-423.	0.8	0

#	ARTICLE	IF	CITATIONS
248	Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. The Journal of Oncopathology, 2014, 2, 37-45.	0.1	0
249	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. Journal of Internal Medicine, 2015, 278, 545-570.	2.7	46
251	Colorectal cancer. Nature Reviews Disease Primers, 2015, 1, 15065.	18.1	1,104
253	Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncology Reports, 2015, 33, 2135-42.	1.2	66
254	Sigmoid adenocarcinoma with metastases to the kidney: Report of a rare case and review of the literature. Oncology Letters, 2015, 10, 1191-1193.	0.8	8
255	Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 682-685.	2.3	2
256	Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis. Molecular and Clinical Oncology, 2015, 3, 959-967.	0.4	9
257	Profile of nintedanib in the treatment of solid tumors: the evidence to date. OncoTargets and Therapy, 2015, 8, 3691.	1.0	58
258	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomarker Insights, 2015, 10s3, BMI.S22436.	1.0	7
259	A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. International Journal of Oncology, 2015, 47, 97-105.	1.4	5
260	Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. Anti-Cancer Drugs, 2015, 26, 872-877.	0.7	15
261	Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer. Neoplasia, 2015, 17, 687-696.	2.3	25
265	Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 308-312.	0.5	8
266	The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. Journal of Translational Medicine, 2015, 13, 199.	1.8	52
267	Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2015, 34, 108.	3.5	54
268	Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. Journal of Experimental and Clinical Cancer Research, 2015, 34, 132.	3.5	37
269	Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer. BMC Research Notes, 2015, 8, 538.	0.6	4
270	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights, 2015, 10s3, BMI.S22430.	1.0	29

#	ARTICLE	IF	CITATIONS
271	Biomarkers of Angiogenesis in Colorectal Cancer. <i>Biomarkers in Cancer</i> , 2015, 7s1, BIC.S25250.	3.6	57
272	Clinical trial end points relevant to patients and society for rare cancers. <i>Clinical Investigation</i> , 2015, 5, 599-612.	0.0	1
273	Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 543-549.	0.6	20
274	Curcumin inhibits lymphangiogenesis in vitro and in vivo. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 2345-2354.	1.5	19
275	Three-Dimensional Ultrasound Molecular Imaging of Angiogenesis in Colon Cancer Using a Clinical Matrix Array Ultrasound Transducer. <i>Investigative Radiology</i> , 2015, 50, 322-329.	3.5	43
276	Systemic Treatment: Maintenance Compared with Holiday. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 85-90.	1.8	3
277	Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. <i>World Journal of Hepatology</i> , 2015, 7, 787.	0.8	140
278	Phase II study of reintroduction of oxaliplatin for&nbsp;advanced colorectal cancer in patients previously&nbsp;treated with oxaliplatin and irinotecan: RE-OPEN study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3099.	2.0	45
279	Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. <i>Wspolczesna Onkologia</i> , 2015, 5, 385-390.	0.7	2
280	Hes1 Increases the Invasion Ability of Colorectal Cancer Cells via the STAT3-MMP14 Pathway. <i>PLoS ONE</i> , 2015, 10, e0144322.	1.1	44
281	The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 835.	1.0	22
282	Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 2407.	1.0	10
283	Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 2361.	1.0	3
284	An Oncology Nursesâ€™ Guide to New Targeted Agents for Metastatic Colorectal Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 571-579.	0.3	3
285	Biologic Therapies in Colorectal Cancer: Indications and Contraindications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e197-e206.	1.8	7
286	A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1653.	2.0	7
287	Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. <i>Cancer Management and Research</i> , 2015, 7, 357.	0.9	4
288	LZ-207, a Newly Synthesized Flavonoid, Induces Apoptosis and Suppresses Inflammation-Related Colon Cancer by Inhibiting the NF-Î³B Signaling Pathway. <i>PLoS ONE</i> , 2015, 10, e0127282.	1.1	6



#	ARTICLE	IF	CITATIONS
289	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0138341.	1.1	16
290	Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI. PLoS ONE, 2015, 10, e0138452.	1.1	9
291	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy, 2015, 8, 2949.	1.0	7
292	Treatment of metastatic colorectal cancer: focus on panitumumab. Cancer Management and Research, 2015, 7, 189.	0.9	14
293	Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer. Case Reports in Oncological Medicine, 2015, 2015, 1-6.	0.2	10
294	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget, 2015, 6, 35589-35601.	0.8	57
296	Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Research and Treatment, 2015, 47, 790-795.	1.3	10
297	Treatment of colorectal cancer in the elderly. World Journal of Gastrointestinal Oncology, 2015, 7, 204.	0.8	90
298	Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resistance Updates, 2015, 20, 39-70.	6.5	83
299	Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Drugs, 2015, 75, 1009-1017.	4.9	18
300	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 619-629.	5.1	574
301	Unraveling the Complexities of Treating Metastatic Colorectal Cancer With Angiogenesis Inhibitors. Clinical Colorectal Cancer, 2015, 14, 131-132.	1.0	1
302	Emerging kinase inhibitors of the treatment of gastric cancer. Expert Opinion on Emerging Drugs, 2015, 20, 479-493.	1.0	13
303	Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 995-1004.	1.5	3
304	The role of regorafenib in metastatic colorectal cancer. Lancet Oncology, The, 2015, 16, 596-597.	5.1	6
305	Integrating biomarkers in colorectal cancer trials in the West and China. Nature Reviews Clinical Oncology, 2015, 12, 553-560.	12.5	11
306	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research, 2015, 21, 4153-4164.	3.2	21
307	Management of regorafenib-related toxicities: a review. Therapeutic Advances in Gastroenterology, 2015, 8, 285-297.	1.4	71

#	ARTICLE	IF	CITATIONS
308	EGFR signaling in colorectal cancer: a clinical perspective. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 0, , 21.	5.5	10
309	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 972-981.	1.2	26
310	Potent antitumor activity of cabozantinib, a <i>MET</i> and <i>VEGFR</i> <sup>2</sup> inhibitor, in a colorectal cancer patient-derived tumor explant model. <i>International Journal of Cancer</i> , 2015, 136, 1967-1975.	2.3	47
311	Comet assay measures of <i>DNA</i> damage as biomarkers of irinotecan response in colorectal cancer in <i>vitro</i> and in <i>vivo</i> . <i>Cancer Medicine</i> , 2015, 4, 1309-1321.	1.3	20
312	Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.. <i>Gastroenterology Report</i> , 2015, 3, gov052.	0.6	21
313	Update on Anti-angiogenesis Therapy in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 378-387.	1.0	9
314	Inhibitors of Angiogenesis. , 2015, , 261-285.		1
315	Protein Targeting Compounds. , 2015, , .		1
316	Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 1710-1719.	1.5	15
317	Are There Strategies to Integrate the Continuum of Care for Metastatic Colorectal Cancer When Resources Are Limited?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 311-316.	1.0	0
318	New hope on the horizon for patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2015, 4, 229-239.	0.8	0
319	The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv216.	3.0	62
320	Progress in defining first-line and maintenance therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 73-74.	12.5	39
321	Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy. <i>Biomaterials</i> , 2015, 42, 161-171.	5.7	32
322	Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. <i>Targeted Oncology</i> , 2015, 10, 199-213.	1.7	46
323	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 257-276.	2.0	37
324	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e985940.	2.1	47
325	Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 129-143.	0.8	14

#	ARTICLE	IF	CITATIONS
326	Pericytes: a double-edged sword in cancer therapy. <i>Future Oncology</i> , 2015, 11, 169-179.	1.1	61
327	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043.	3.2	31
328	Circulating Endothelial Cells and Their Subpopulations: Role as Predictive Biomarkers in Antiangiogenic Therapy for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 11-17.	1.0	28
329	Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 89-94.	1.3	194
330	The role of the PI3K pathway in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 18-30.	2.0	96
331	Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2015, 22, 2195-2200.	0.7	38
332	Regorafenib: start low and go slow. <i>Targeted Oncology</i> , 2015, 10, 445-447.	1.7	20
333	Broad targeting of angiogenesis for cancer prevention and therapy. <i>Seminars in Cancer Biology</i> , 2015, 35, S224-S243.	4.3	375
334	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015, 26, 724-730.	0.6	136
335	Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 253-267.	1.0	43
337	Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 153-169.	1.4	50
338	Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 479-491.	2.0	2
339	Peritoneal Surface Disease with Synchronous Hepatic Involvement Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2015, 22, 1634-1638.	0.7	28
340	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). <i>Pharmaceutical Research</i> , 2015, 32, 2205-2216.	1.7	53
341	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. <i>Investigational New Drugs</i> , 2015, 33, 740-750.	1.2	94
342	First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1112-1118.	0.8	144
343	Renal effects of targeted anticancer therapies. <i>Nature Reviews Nephrology</i> , 2015, 11, 354-370.	4.1	95
344	The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. <i>Autophagy</i> , 2015, 11, 1373-1388.	4.3	49

#	ARTICLE	IF	CITATIONS
345	Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1048-1056.	1.9	22
346	Current controversies in the management of metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 659-677.	1.1	17
348	Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 114-124.	2.0	15
349	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 251-263.	2.0	8
350	The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1359-1370.	1.4	13
351	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 479-496.	2.7	101
352	Novel drugs in clinical development for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1075-1082.	1.9	34
353	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology, The</i> , 2015, 16, 937-948.	5.1	286
354	Improving Patient Outcomes with Regorafenib for Metastatic Colorectal Cancer - Patient Selection, Dosing, Patient Education, Prophylaxis, and Management of Adverse Events. <i>Oncology Research and Treatment</i> , 2015, 38, 300-308.	0.8	14
355	Circulating DNA biomarkers: a primer for metastatic colorectal cancer?. <i>Lancet Oncology, The</i> , 2015, 16, 878-879.	5.1	3
356	Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. <i>Molecular Therapy</i> , 2015, 23, 1532-1540.	3.7	140
357	The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2015, 7, 439-449.	1.7	2
358	Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. <i>Oncologist</i> , 2015, 20, 660-673.	1.9	436
359	Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 579-594.	1.1	17
360	Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 273-276.	1.4	11
361	The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 81-100.	0.7	4
362	Metastatic Colorectal Cancer: Current State and Future Directions. <i>Journal of Clinical Oncology</i> , 2015, 33, 1809-1824.	0.8	418
363	Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion. <i>Gastroenterology</i> , 2015, 148, 1438-1451.e8.	0.6	114

#	ARTICLE	IF	CITATIONS
364	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2015, 51, 942-949.	1.3	47
366	Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 1523-1531.	0.9	41
367	Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 993-1004.	1.1	12
369	Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. <i>Targeted Oncology</i> , 2015, 10, 453-465.	1.7	18
370	Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy. <i>Radiologia Medica</i> , 2015, 120, 767-776.	4.7	19
371	Identifying Appropriate Colorectal Cancer-Associated Antigens for the Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 29-36.	1.0	6
372	First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 54-69.	1.0	0
373	Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 314-316.	0.6	7
374	A patient with rectal cancer and liver metastasis who developed interstitial pneumonia after regorafenib administration. <i>International Cancer Conference Journal</i> , 2015, 4, 206-210.	0.2	1
375	Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. <i>BMC Cancer</i> , 2015, 15, 127.	1.1	22
376	Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. <i>Journal of Translational Medicine</i> , 2015, 13, 57.	1.8	49
377	Eruptive nevi and hair depigmentation related to regorafenib. <i>European Journal of Dermatology</i> , 2015, 25, 85-86.	0.3	11
379	Incidence and risk of xerosis with targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 656-667.	0.6	39
380	Regulation of vascular endothelial growth factor in prostate cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R107-R123.	1.6	47
381	Liver transplantation in treatment of colorectal liver metastases. <i>Hepatic Oncology</i> , 2015, 2, 181-190.	4.2	7
382	Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Espa±ol Multidisciplinar en Cancer Digestivo (GEMCAD). <i>Colorectal Cancer</i> , 2015, 4, 97-112.	0.8	0
383	Bevacizumab for metastatic colon cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 363-366.	0.7	9
384	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 207-239.	1.0	548

#	ARTICLE	IF	CITATIONS
385	Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 18.	1.3	11
386	Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. <i>Clinical Cancer Research</i> , 2015, 21, 2975-2983.	3.2	63
387	Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2015, 33, 1242-1247.	1.2	26
389	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5499-5510.	3.2	18
390	Alopecia in patients treated with molecularly targeted anticancer therapies. <i>Annals of Oncology</i> , 2015, 26, 2496-2502.	0.6	48
391	Markers in Colorectal Cancer and Clinical Trials Based Upon Them. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 317-325.	1.0	0
392	Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 925-932.	1.1	40
393	Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK. <i>Journal of Medical Economics</i> , 2015, 18, 797-804.	1.0	10
394	STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 496.	1.1	20
395	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1283-1292.	1.1	12
396	Targeting FGF receptors in colorectal cancer: from bench side to bed side. <i>Future Oncology</i> , 2015, 11, 1373-1379.	1.1	5
397	Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. <i>Annals of Oncology</i> , 2015, 26, 2017-2026.	0.6	104
398	A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 601.	1.1	13
399	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
400	Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios. <i>Future Oncology</i> , 2015, 11, 2625-2628.	1.1	4
401	How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). <i>Current Colorectal Cancer Reports</i> , 2015, 11, 151-159.	1.0	2
402	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 217-224.	1.0	1
403	KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers. <i>Gastroenterology</i> , 2015, 149, 705-717.e2.	0.6	35

#	ARTICLE	IF	CITATIONS
404	Vascular and Metabolic Implications of Novel Targeted Cancer Therapies. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1160-1178.	1.2	157
405	Gastrointestinal and Pancreatobiliary Tumors. , 2015, , 375-406.		0
406	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncology</i> , The, 2015, 16, 1306-1315.	5.1	835
407	An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1307-1320.	1.9	7
408	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3727-3732.	0.8	86
409	<i>KRAS</i> exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. <i>Future Oncology</i> , 2015, 11, 1919-1929.	1.1	11
410	Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project. <i>Oncology</i> , 2015, 88, 103-121.	0.9	9
411	Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis. <i>Investigational New Drugs</i> , 2015, 33, 1144-1147.	1.2	10
412	Bevacizumab beyond first disease progression in metastatic colorectal cancer: a review of recent clinical trial data. <i>Colorectal Cancer</i> , 2015, 4, 13-25.	0.8	0
413	Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. <i>Clinical Lung Cancer</i> , 2015, 16, 514-522.	1.1	10
414	Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNF in colorectal cancer. , 2015, 156, 1-9.		64
415	Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1267-1281.	1.1	17
416	MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer. <i>Immunotherapy</i> , 2015, 7, 1133-1134.	1.0	9
417	Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol. <i>BMJ Open</i> , 2015, 5, e007189-e007189.	0.8	13
419	Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. <i>Cancer Biology and Therapy</i> , 2015, 16, 1726-1737.	1.5	75
420	Regorafenib suppresses sinusoidal obstruction syndrome in rats. <i>Journal of Surgical Research</i> , 2015, 193, 693-703.	0.8	22
421	Is More Not Better?. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 85-116.	0.9	3
422	Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2015, 17, 384-392.	1.2	13

#	ARTICLE	IF	CITATIONS
423	Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC). Hematology/Oncology Clinics of North America, 2015, 29, 43-60.	0.9	24
425	Recent Therapeutic Advances in the Treatment of Colorectal Cancer. Annual Review of Medicine, 2015, 66, 83-95.	5.0	162
426	Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer. Surgical Oncology Clinics of North America, 2015, 24, 199-214.	0.6	7
427	Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes and Diseases, 2015, 2, 4-12.	1.5	94
428	Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations. Tumor Biology, 2015, 36, 21-31.	0.8	4
429	Gastric cancer: past progress and present challenges. Gastric Cancer, 2015, 18, 205-209.	2.7	7
430	A novel germline mutation of PDGFR- $\beta$ might be associated with clinical response of colorectal cancer to regorafenib. Annals of Oncology, 2015, 26, 246-248.	0.6	8
431	BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2016, 29, 173-179.	0.5	7
432	Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer. OncoTargets and Therapy, 2016, Volume 9, 4113-4120.	1.0	3
433	Perspective: How to Improve Patient Selection in Refractory Metastatic Colorectal Cancer. Tumori, 2016, 102, P1-P2.	0.6	0
434	Role of targeted therapy in metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 642.	0.8	80
435	Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2016, Volume 3, 31-36.	1.8	32
436	Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy. Neoplasma, 2016, 63, 173-82.	0.7	27
437	Eastern Canadian Colorectal Cancer Consensus Conference 2013: Emerging Therapies in the Treatment of Pancreatic, Rectal, and Colorectal Cancers. Current Oncology, 2016, 23, 52-55.	0.9	1
438	Targeting Tumor Angiogenesis in Gastrointestinal Malignancies. Current Angiogenesis, 2016, 4, 37-45.	0.1	0
439	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	0.8	29
440	Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Oncotarget, 2016, 7, 64136-64147.	0.8	46
441	Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma. Annals of Thoracic and Cardiovascular Surgery, 2016, 22, 6-11.	0.3	9



#	ARTICLE	IF	CITATIONS
442	Multimodality Targeting of Glioma Cells. , 2016, , 55-72.		0
443	Targeting angiogenesis in gastrointestinal tumors: current challenges. Translational Gastroenterology and Hepatology, 2016, 1, 67-67.	1.5	15
444	Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget, 2016, 7, 34811-34823.	0.8	43
445	Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome. Oncotarget, 2016, 7, 21922-21938.	0.8	59
446	Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World Journal of Gastroenterology, 2016, 22, 5400.	1.4	6
447	Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. BioMed Research International, 2016, 2016, 1-14.	0.9	19
448	Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. Gastroenterology Research and Practice, 2016, 2016, 1-9.	0.7	9
449	Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT/Overlock 10 Tf 50	1.0	31
450	Targeting gastrointestinal stromal tumors: the role of regorafenib. OncoTargets and Therapy, 2016, 9, 3009.	1.0	5
451	Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. OncoTargets and Therapy, 2016, 9, 1899.	1.0	44
452	Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 887.	1.4	13
454	An update on clinical oncology for the non-oncologist. Einstein (Sao Paulo, Brazil), 2016, 14, 294-299.	0.3	2
455	Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget, 2016, 7, 67661-67673.	0.8	43
456	The emerging role of immunotherapy in colorectal cancer. Annals of Translational Medicine, 2016, 4, 305-305.	0.7	63
457	Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothed and GLI Inhibitors. Cancers, 2016, 8, 22.	1.7	476
458	KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer. Cureus, 2016, 8, e478.	0.2	20
459	Molecular-targeted Therapies in Gastrointestinal Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1051-1060.	0.0	0
460	Evidence-based Clinical Management of Acute Malignant Colorectal Obstruction. Journal of Clinical Gastroenterology, 2016, 50, 273-285.	1.1	43

#	ARTICLE	IF	CITATIONS
461	Mitomycin-C+fluoropyrimidines in heavily pretreated metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 488-495.	0.7	3
462	Media Reporting of Practice—Changing Clinical Trials in Oncology: A North American Perspective. <i>Oncologist</i> , 2016, 21, 269-278.	1.9	5
463	Cardiac safety and toxicity minimization of regorafenib treatment. <i>Colorectal Cancer</i> , 2016, 5, 1-3.	0.8	1
464	An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. <i>Current Oncology Reports</i> , 2016, 18, 49.	1.8	5
465	Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. <i>Journal of Cellular Physiology</i> , 2016, 231, 1097-1105.	2.0	43
466	Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. <i>BMC Cancer</i> , 2016, 16, 412.	1.1	89
467	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
468	Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. <i>ESMO Open</i> , 2016, 1, e000084.	2.0	9
469	A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study). <i>Oncology</i> , 2016, 91, 24-30.	0.9	13
470	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq1 1 0z784314 rg5T /Ove		
471	Computed tomography evaluation of morphological changes, clinical response and survival in colorectal cancer liver metastasis treated by regorafenib: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 807-810.	0.4	2
472	Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2016, 2, 15.	0.4	7
473	Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. <i>Scientific Reports</i> , 2016, 6, 34523.	1.6	17
474	Biomarker in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 156-164.	1.0	35
475	Y90 Radioembolization in chemo-refractory metastatic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. <i>BMC Cancer</i> , 2016, 16, 509.	1.1	30
476	Ramucirumab: Boon or bane. <i>Journal of the Egyptian National Cancer Institute</i> , 2016, 28, 133-140.	0.6	9
477	Drug-induced hepatotoxicity in cancer patients - implication for treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1219-1238.	1.0	52
478	Precision Medicine in Gastrointestinal Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 449-460.	1.2	3

#	ARTICLE	IF	CITATIONS
480	Review on TAS-102 development and its use for metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 91-97.	2.0	6
481	Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 659-670.	0.5	0
482	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. <i>Annals of Oncology</i> , 2016, 27, 1456-1466.	0.6	51
483	The Economics of Personalized Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 123-129.	1.0	2
485	Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. <i>Clinical Colorectal Cancer</i> , 2016, 15, e109-e115.	1.0	20
486	Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1792-1801.	3.3	17
487	Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 230-242.	1.4	58
488	A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 4574-4584.	3.2	13
489	Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. <i>Canadian Journal of Cardiology</i> , 2016, 32, 831-841.	0.8	190
490	Comparison of the crystal structures of the potent anticancer and anti-angiogenic agent regorafenib and its monohydrate. <i>Acta Crystallographica Section C, Structural Chemistry</i> , 2016, 72, 291-296.	0.2	6
491	Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?. <i>Clinical and Translational Oncology</i> , 2016, 18, 1072-1081.	1.2	9
492	Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. <i>Cancer Cell</i> , 2016, 29, 587-601.	7.7	375
493	Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 26.	1.3	20
494	TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 2835-2839.	3.2	12
495	Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. <i>Annals of Oncology</i> , 2016, 27, 1273-1279.	0.6	65
496	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	5.1	778
497	Oral drugs in the treatment of metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1351-1361.	0.9	21
498	High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art. <i>Digestive and Liver Disease</i> , 2016, 48, 1503-1505.	0.4	35

#	ARTICLE	IF	CITATIONS
499	Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2016, 64, 167-174.	1.3	41
501	Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. <i>Cancer Medicine</i> , 2016, 5, 3176-3185.	1.3	67
502	Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 194-199.	3.4	9
503	Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2016, 5, 635-640.	0.4	13
504	Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1389-1395.	1.3	0
505	Regorafenib induced severe toxic hepatitis: characterization and discussion. <i>Liver International</i> , 2016, 36, 1590-1594.	1.9	23
506	Combined Use of Oligopeptides, Fragment Libraries, and Natural Compounds: A Comprehensive Approach To Sample the Druggability of Vascular Endothelial Growth Factor. <i>ChemMedChem</i> , 2016, 11, 928-939.	1.6	10
507	A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 577-584.	1.1	12
508	Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. <i>Cancer Science</i> , 2016, 107, 601-608.	1.7	43
509	Smart Materials for Controlled Drug Release. , 2016, , 98-135.		0
510	The rapidly escalating cost of treating colorectal cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 33-40.	0.7	24
511	Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001016.	0.5	5
512	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. <i>Visceral Medicine</i> , 2016, 32, 178-183.	0.5	32
513	Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. <i>Journal of Surgical Oncology</i> , 2016, 114, 655-663.	0.8	43
514	Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer. <i>Drugs</i> , 2016, 76, 1393-1402.	4.9	51
515	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 267-282.	1.0	7
516	Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism. <i>Clinical Colorectal Cancer</i> , 2016, 15, e229-e234.	1.0	4
517	Targeted Therapy of Colorectal Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 796-802.	0.8	38

#	ARTICLE	IF	CITATIONS
518	Rectal gastrointestinal stromal tumor with metastasis to the penis: Case report and review of literature. <i>International Journal of Surgery Case Reports</i> , 2016, 29, 172-175.	0.2	4
520	Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter?. <i>Journal of Chemotherapy</i> , 2016, 28, 321-327.	0.7	4
521	TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review. <i>Clinical Colorectal Cancer</i> , 2016, 15, 292-297.	1.0	13
522	The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 323-328.	0.8	4
523	Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type <i>KRAS</i> Unresectable Metastatic Colorectal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e710-e723.	2.5	20
524	Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1321-1340.	1.4	17
525	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1732-1742.	5.1	200
526	MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 62-76.	1.1	80
527	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. <i>Cancer Treatment Reviews</i> , 2016, 51, 54-62.	3.4	24
528	Targeted therapy and elderly people: A review. <i>European Journal of Cancer</i> , 2016, 69, 199-215.	1.3	34
529	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
530	Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. <i>Scientific Reports</i> , 2016, 6, 35308.	1.6	9
531	Cancer Drug Discovery. , 2016, , .		6
532	Novel investigational therapies for treating biliary tract carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1423-1436.	1.9	5
533	Colorectal cancer and the KIR genes in the human genome: A meta-analysis. <i>Genomics Data</i> , 2016, 10, 118-126.	1.3	12
535	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016, 6, 25195.	1.6	25
536	Management of patients with colorectal liver metastasis in eleven questions and answers. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1277-1290.	1.1	3
537	Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338.		0

#	ARTICLE	IF	CITATIONS
538	Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?. ESMO Open, 2016, 1, e000124.	2.0	7
539	Single-Agent Therapies After Standard Combination Regimens. Cancer Journal (Sudbury, Mass ), 2016, 22, 205-210.	1.0	1
540	Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin. Current Opinion in Oncology, 2016, 28, 437-440.	1.1	6
541	Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer. The Cochrane Library, 2016, , .	1.5	0
542	Targeting Angiogenesis in Colorectal Cancer. Cancer Journal (Sudbury, Mass ), 2016, 22, 182-189.	1.0	29
543	Value in Colorectal Cancer Treatment. Cancer Journal (Sudbury, Mass ), 2016, 22, 232-235.	1.0	7
544	Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where are We Now and What should be Next?. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S34542.	0.6	20
545	Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S38335.	0.6	19
546	Metastatic Spread Emerging From Liver Metastases of Colorectal Cancer. Annals of Surgery, 2016, 263, 345-352.	2.1	26
547	Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. European Journal of Cancer, 2016, 63, 74-87.	1.3	13
548	Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor. Oncology Letters, 2016, 11, 939-944.	0.8	13
549	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. Journal of Clinical Oncology, 2016, 34, 2728-2735.	0.8	183
550	A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 259-269.	1.1	45
551	Inhibitors of Angiogenesis. Advances in Experimental Medicine and Biology, 2016, 917, 261-285.	0.8	2
552	Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment. Journal of Cancer Research and Clinical Oncology, 2016, 142, 699-706.	1.2	16
553	Management of disappearing colorectal liver metastases. European Journal of Surgical Oncology, 2016, 42, 1798-1805.	0.5	38
554	Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 321-328.e1.	1.0	59
555	Current targeted therapies in the treatment of advanced colorectal cancer: a review. Therapeutic Advances in Medical Oncology, 2016, 8, 276-293.	1.4	72

#	ARTICLE	IF	CITATIONS
557	The state of regional therapy in the management of metastatic colorectal cancer to the liver. Expert Review of Anticancer Therapy, 2016, 16, 229-245.	1.1	5
558	Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes. Cancer Chemotherapy and Pharmacology, 2016, 77, 905-926.	1.1	15
559	A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Expert Review of Clinical Pharmacology, 2016, 9, 355-365.	1.3	11
560	Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival. Acta Oncologica, 2016, 55, 486-495.	0.8	22
561	From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. Clinical Colorectal Cancer, 2016, 15, 104-115.	1.0	20
562	Number needed to treat for pricing costly anticancer drugs: the example of regorafenib in metastatic colorectal cancer. Annals of Oncology, 2016, 27, 747-748.	0.6	3
563	<sup>90</sup> Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 665-671.	2.8	79
564	Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer, 2016, 19, 329-338.	2.7	242
565	Hand-Foot Skin Reaction to Regorafenib. Actas Dermo-sifilograficas, 2016, 107, 71-73.	0.2	3
566	Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 2016, 15, 385-403.	21.5	724
567	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clinical Colorectal Cancer, 2016, 15, 1-6.	1.0	72
568	Current and advancing treatments for metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2016, 16, 93-110.	1.4	31
569	The development of new agents and molecular classifications. Nature Reviews Clinical Oncology, 2016, 13, 69-70.	12.5	21
570	Regorafenib in the treatment of colorectal cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 137-145.	0.9	10
571	Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow". Targeted Oncology, 2016, 11, 127-128.	1.7	0
572	Comment on: "Regorafenib: Start Low and Go Slow". Targeted Oncology, 2016, 11, 123-125.	1.7	2
573	TAS-102: a novel antimetabolite for the 21st century. Future Oncology, 2016, 12, 153-163.	1.1	17
574	MGMT in colorectal cancer: a promising component of personalized treatment. Tumor Biology, 2016, 37, 11443-11456.	0.8	11

#	ARTICLE	IF	CITATIONS
575	Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. <i>British Journal of Cancer</i> , 2016, 114, 1003-1011.	2.9	16
576	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 557-571.	1.1	7
577	Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. <i>Clinical Oncology</i> , 2016, 28, 283-291.	0.6	3
578	Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. <i>Clinical Colorectal Cancer</i> , 2016, 15, 195-203.	1.0	268
579	Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. <i>Acta Oncologica</i> , 2016, 55, 480-485.	0.8	12
580	Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report. <i>Oncology Letters</i> , 2016, 11, 85-88.	0.8	6
581	Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report. <i>Oncology Letters</i> , 2016, 11, 231-233.	0.8	17
582	Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells. <i>International Journal of Oncology</i> , 2016, 48, 1477-1484.	1.4	8
583	Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 449-456.	1.5	7
584	Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet, The</i> , 2016, 388, 518-529.	6.3	663
585	Optimizing Colorectal Cancer Care in Older Patients. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 9-17.	1.0	0
586	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1062-1067.	0.6	35
587	Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 33.	0.4	41
588	Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. <i>Annals of Oncology</i> , 2016, 27, 1074-1081.	0.6	72
589	Novel anti-angiogenic therapeutic strategies in colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 507-520.	1.9	62
590	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 122-136.	2.0	24
591	Pharmacologic resistance in colorectal cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 57-84.	1.4	385
592	Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. <i>Annals of Oncology</i> , 2016, 27, 267-274.	0.6	105



#	ARTICLE	IF	CITATIONS
593	Reacción cutánea mano-pie por regorafenib. Actas Dermo-sifiliográficas, 2016, 107, 71-73.	0.2	5
594	Management of Colorectal Cancer in Older Adults. Clinics in Geriatric Medicine, 2016, 32, 97-111.	1.0	16
595	Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Critical Reviews in Oncology/Hematology, 2016, 97, 85-95.	2.0	19
596	Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. Clinical Colorectal Cancer, 2016, 15, 91-94.e1.	1.0	18
597	Targeting the Wnt signaling pathway in colorectal cancer. Expert Opinion on Therapeutic Targets, 2016, 20, 419-429.	1.5	54
598	A Practical Approach to Fatigue Management in Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 275-285.	1.0	34
599	Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 260-265.	0.6	3
600	Immunomodulatory Activity of VEGF in Cancer. International Review of Cell and Molecular Biology, 2017, 330, 295-342.	1.6	153
601	Translating genomic profiling to gastrointestinal cancer treatment. Future Oncology, 2017, 13, 919-934.	1.1	7
602	Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Investigational New Drugs, 2017, 35, 451-462.	1.2	44
603	High expression of ADAMTS5 is a potent marker for lymphatic invasion and lymph node metastasis in colorectal cancer. Molecular and Clinical Oncology, 2017, 6, 130-134.	0.4	12
604	The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong. Postgraduate Medical Journal, 2017, 93, 395-400.	0.9	13
605	Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. Future Oncology, 2017, 13, 415-423.	1.1	18
606	Advanced colorectal cancer treatment options beyond standard systemic therapy. Lancet Oncology, The, 2017, 18, 157-159.	5.1	8
607	Second-line systemic therapy for metastatic colorectal cancer. The Cochrane Library, 2017, 1, CD006875.	1.5	26
608	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
609	New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. Autophagy, 2017, 13, 781-819.	4.3	117
610	High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Science Translational Medicine, 2017, 9, .	5.8	297

#	ARTICLE	IF	CITATIONS
611	Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. <i>Cancer Research</i> , 2017, 77, 2512-2521.	0.4	118
612	Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. <i>Drugs and Aging</i> , 2017, 34, 173-189.	1.3	5
613	Evaluation of molecular chaperone drug function: Regorafenib and $\beta$ -cyclodextrins. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 153, 61-68.	2.5	11
614	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50
615	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS ( KRAS/NRAS ) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	1.0	13
616	Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102). <i>Clinical Colorectal Cancer</i> , 2017, 16, 85-92.	1.0	14
617	Focused Ultrasound-Triggered Release of Tyrosine Kinase Inhibitor From Thermosensitive Liposomes for Treatment of Renal Cell Carcinoma. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 1355-1362.	1.6	19
618	Metronomic chemotherapy in metastatic colorectal cancer. <i>Cancer Letters</i> , 2017, 400, 319-324.	3.2	33
619	Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion. <i>Visceral Medicine</i> , 2017, 33, 47-53.	0.5	22
620	Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. <i>Nature Communications</i> , 2017, 8, 14262.	5.8	260
621	Clinical and molecular assessment of regorafenib monotherapy. <i>Oncology Reports</i> , 2017, 37, 2506-2512.	1.2	15
623	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. <i>British Journal of Cancer</i> , 2017, 116, 1279-1286.	2.9	37
624	A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. <i>Cancer Investigation</i> , 2017, 35, 386-392.	0.6	8
625	How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. <i>Annals of Oncology</i> , 2017, 28, 2077-2085.	0.6	30
626	Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit. <i>Clinical Colorectal Cancer</i> , 2017, 16, 372-376.	1.0	19
627	Cardiotoxicity of Anticancer Therapies. , 2017, , 15-42.		3
628	Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2632-2641.	1.6	20
629	Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?. <i>European Journal of Endocrinology</i> , 2017, 177, 85-92.	1.9	23

#	ARTICLE	IF	CITATIONS
630	Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 54-60.	3.4	99
631	Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 42-48.	1.4	34
632	Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases. <i>Molecular and Clinical Oncology</i> , 2017, 6, 63-66.	0.4	7
633	The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis. <i>Matrix Biology</i> , 2017, 64, 40-53.	1.5	61
634	Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. <i>Journal of Hematology and Oncology</i> , 2017, 10, 86.	6.9	64
635	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2017, , 1-16.		0
636	Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2017, 16, 377-380.	1.0	12
637	Emergence of <i>TNIP</i> inhibitors in cancer therapeutics. <i>Cancer Science</i> , 2017, 108, 818-823.	1.7	36
638	Epithelial Src homology region 2 domain-containing phosphatase <sup>1</sup> restrains intestinal growth, secretory cell differentiation, and tumorigenesis. <i>FASEB Journal</i> , 2017, 31, 3512-3526.	0.2	6
639	Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e39-e44.	1.0	12
640	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	6.3	2,771
641	Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 149-160.	0.7	93
642	VEGF Ligands. , 2017, , 639-658.		0
643	Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1999-2007.	1.9	12
644	Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 81-90.	1.1	6
645	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945
646	Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 534-539.	0.9	3
647	An overall review of targeted therapy in solid cancers. <i>Current Medicine Research and Practice</i> , 2017, 7, 99-105.	0.1	9

#	ARTICLE	IF	CITATIONS
648	Phase 1 study of <sc>OCV</sc>â€C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer. <i>Cancer Science</i> , 2017, 108, 1013-1021.	1.7	14
649	Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review. <i>Surgical Oncology</i> , 2017, 26, 268-275.	0.8	47
650	Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2017, 6, 365-372.	0.4	21
651	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 370-398.	2.3	707
652	Exposureâ€response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S149-S153.	1.9	18
653	An Expanding Role for Immunotherapy in Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 401-410.	2.3	47
654	Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. <i>Lancet Oncology</i> , The, 2017, 18, 887-894.	5.1	108
655	Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 59-66.	2.0	19
657	A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases. <i>Current Treatment Options in Oncology</i> , 2017, 18, 42.	1.3	7
658	High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma. <i>Pathology Research and Practice</i> , 2017, 213, 895-899.	1.0	29
659	Revision of the concept of antiâ€angiogenesis and its applications in tumor treatment. <i>Chronic Diseases and Translational Medicine</i> , 2017, 3, 33-40.	0.9	39
660	REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study. <i>Clinical Colorectal Cancer</i> , 2017, 16, 316-323.	1.0	16
661	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. <i>Scientific Reports</i> , 2017, 7, 45703.	1.6	22
662	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	1.4	85
664	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482
665	Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. <i>Investigational New Drugs</i> , 2017, 35, 491-498.	1.2	7
666	Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. <i>Cell Communication and Signaling</i> , 2017, 15, 9.	2.7	37
667	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. <i>Cancer Letters</i> , 2017, 396, 145-154.	3.2	56

#	ARTICLE	IF	CITATIONS
668	From tumour heterogeneity to advances in precision treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 235-246.	12.5	466
669	Current and future biomarkers in the treatment of colorectal cancer. <i>Acta Clinica Belgica</i> , 2017, 72, 103-115.	0.5	30
670	Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review. <i>Annals of Oncology</i> , 2017, 28, 478-486.	0.6	28
671	Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 107-116.	1.1	4
672	Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2017, 16, e109-e113.	1.0	7
673	Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?. <i>Journal of Chemotherapy</i> , 2017, 29, 102-105.	0.7	14
674	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 53, 120-127.	3.4	178
675	Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). <i>International Journal of Cancer</i> , 2017, 140, 1918-1925.	2.3	15
676	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
677	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 319-327.	1.0	11
678	Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. <i>Clinical Therapeutics</i> , 2017, 39, 2135-2145.	1.1	12
679	Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer. <i>Oncology</i> , 2017, 93, 191-196.	0.9	3
680	Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1295-1305.	1.9	5
681	Introduction to Gastrointestinal Diseases Vol. 2. , 2017, , .		1
682	Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer. <i>Case Reports in Oncology</i> , 2017, 10, 790-794.	0.3	4
683	Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials. <i>Investigational New Drugs</i> , 2017, 35, 834-838.	1.2	3
684	Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 50-58.	2.0	17
685	TAS-102 and the quest for predictive biomarkers. <i>ESMO Open</i> , 2017, 2, e000263.	2.0	4

#	ARTICLE	IF	CITATIONS
686	Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). <i>European Journal of Cancer</i> , 2017, 84, 262-269.	1.3	8
687	Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8234-E8243.	3.3	236
688	Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma. <i>Neuroendocrinology</i> , 2017, 105, 426-434.	1.2	41
689	Clinical pharmacology of anti-angiogenic drugs in oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 75-93.	2.0	13
690	An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1467-1476.	0.9	23
691	Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling. <i>Organogenesis</i> , 2017, 13, 183-191.	0.4	3
692	Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216.		0
693	Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer. <i>Oncology</i> , 2017, 93, 354-358.	0.9	6
694	Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 661-671.	1.1	6
695	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	5.1	2,058
696	Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1209-1217.	0.8	10
697	Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis. <i>International Journal of Clinical Oncology</i> , 2017, 22, 807-816.	1.0	3
698	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	1.3	25
699	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) â€“ Multidisciplinary Management. <i>Colorectal Disease</i> , 2017, 19, 37-66.	0.7	77
701	Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 220-224.	1.2	4
702	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017, 2, e000147.	2.0	36
703	European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. <i>ESMO Open</i> , 2017, 2, e000190.	2.0	13
705	Erythema multiforme induced by regorafenib. <i>Journal of General and Family Medicine</i> , 2017, 18, 90-91.	0.3	3

#	ARTICLE	IF	CITATIONS
706	Recent developments in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 551-564.	1.4	82
707	A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 790-803.	1.6	38
708	Liver Transplantation for Unresectable Disease. , 2017, , 289-299.		0
709	An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 667-687.	0.6	24
710	Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 1357-1366.	0.8	6
711	A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 1125-1134.	1.4	8
712	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. <i>Seminars in Oncology</i> , 2017, 44, 114-128.	0.8	14
713	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017, 2, e000177.	2.0	27
714	Unexpected side effect in mCRC. <i>Medicine (United States)</i> , 2017, 96, e6522.	0.4	5
715	Treatment of metastatic refractory colorectal cancer following regorafenib failure. <i>Molecular and Clinical Oncology</i> , 2017, 7, 308-312.	0.4	6
716	Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 2491-2498.	0.8	4
717	The role of stereotactic body radiation therapy in oligometastatic colorectal cancer. <i>Medicine (United States)</i> , 2017, 96, e9023.	0.4	14
718	Evidence-Based Review of Nonsurgical Management of Colorectal Cancer Liver Metastasis and Evolving Role of Interventional Radiology. <i>Digestive Disease Interventions</i> , 2017, 01, 184-194.	0.3	0
719	Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction. <i>Medicine (United States)</i> , 2017, 96, e8285.	0.4	5
720	Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 325-333.	1.0	0
721	The potential role of nintedanib in treating colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1153-1162.	0.9	15
722	Targeting FGFR in Squamous Cell Carcinoma of the Lung. <i>Targeted Oncology</i> , 2017, 12, 741-755.	1.7	21
723	Kallistatin exerts anti-lymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation. <i>International Journal of Oncology</i> , 2017, 50, 2000-2010.	1.4	10

#	ARTICLE	IF	CITATIONS
724	Tumour growth increased following antiangiogenic interruption. <i>Anti-Cancer Drugs</i> , 2017, 28, 1062-1065.	0.7	2
725	Protracted inhibition of vascular endothelial growth factor signaling improves survival in metastatic colorectal cancer: A systematic review. <i>Journal of Translational Internal Medicine</i> , 2017, 5, 18-26.	1.0	7
726	Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues. <i>Diagnostic Pathology</i> , 2017, 12, 6.	0.9	26
727	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 22.	6.9	50
728	Cost effectiveness of regorafenib as secondâ€line therapy for patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3725-3731.	2.0	66
729	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , 2017, 12, 525-533.	1.7	15
730	Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 361-368.	1.2	26
731	Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. <i>Cancer Letters</i> , 2017, 386, 100-109.	3.2	32
732	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017, 28, 555-561.	0.6	43
733	FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. <i>Oncogene</i> , 2017, 36, 787-796.	2.6	134
734	Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Caseâ€Control Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 150-158.	0.7	37
735	The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. <i>Clinical Colorectal Cancer</i> , 2017, 16, 38-43.	1.0	18
736	Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. <i>Targeted Oncology</i> , 2017, 12, 89-95.	1.7	15
737	Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. <i>Clinical Colorectal Cancer</i> , 2017, 16, e15-e22.	1.0	64
738	Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. <i>Kidney International Reports</i> , 2017, 2, 108-123.	0.4	72
739	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 106-126.	1.4	36
740	Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 757-764.	3.3	27
741	Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 147-153.	0.6	11



#	ARTICLE	IF	CITATIONS
742	Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. <i>ESMO Open</i> , 2017, 2, e000229.	2.0	14
743	Antiangiogenic therapies in colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 213-217.	0.3	3
744	Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer. <i>ESMO Open</i> , 2017, 2, e000205.	2.0	1
746	Interactions of phytic acid with anticancer drug targets. <i>International Journal of Computational Biology and Drug Design</i> , 2017, 10, 49.	0.3	0
747	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. <i>BMJ: British Medical Journal</i> , 2017, 359, j4530.	2.4	423
748	10. Gastrointestinale Onkologie im Alter. , , .		0
749	Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2â€™Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	5
750	Real-Life Treatment of Metastatic Colorectal Cancer with Regorafenib: A Single-Centre Review. <i>Current Oncology</i> , 2017, 24, 234-239.	0.9	9
751	Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. <i>Frontiers in Pharmacology</i> , 2016, 07, 519.	1.6	59
752	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017, 8, 354.	1.6	165
753	Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 752.	1.8	86
754	A single institute retrospective trial of concurrent chemotherapy with SIR-SpheresÂ® versus SIR-SpheresÂ® alone in chemotherapy-resistant colorectal cancer liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 608-613.	0.6	3
755	Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1522.	1.8	23
757	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 101.	1.8	65
758	The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives. <i>Current Pharmaceutical Design</i> , 2017, 23, 2314-2320.	0.9	10
759	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 41-55.	0.7	11
760	Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. <i>PLoS ONE</i> , 2017, 12, e0176139.	1.1	30
761	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. <i>PLoS ONE</i> , 2017, 12, e0183639.	1.1	2

#	ARTICLE	IF	CITATIONS
762	Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor. <i>Journal of Medical Investigation</i> , 2017, 64, 262-265.	0.2	16
763	Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. <i>Oncology Research</i> , 2017, 25, 673-679.	0.6	5
764	Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis. <i>Molecular Cancer</i> , 2017, 16, 176.	7.9	211
765	Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 227.	0.4	8
766	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. <i>Chinese Journal of Cancer</i> , 2017, 36, 97.	4.9	28
767	Correlation analysis between liver metastasis and serum levels of miR-200 and miR-141 in patients with colorectal cancer. <i>Molecular Medicine Reports</i> , 2017, 16, 7791-7795.	1.1	12
768	The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. <i>Journal of Cancer</i> , 2017, 8, 1410-1416.	1.2	6
769	Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4599-4605.	1.0	5
770	Emerging combination therapies for metastatic colorectal cancer &ndash; impact of trifluridine/tipiracil. <i>Cancer Management and Research</i> , 2017, Volume 9, 461-469.	0.9	8
771	Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. <i>Journal of Oncology Practice</i> , 2017, 13, e653-e665.	2.5	31
772	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3338-3346.	0.8	69
773	Promise of Wearable Physical Activity Monitors in Oncology Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 82-89.	2.5	77
774	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	2.3	26
775	Low expression of the GOPC is a poor prognostic marker in colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 4483-4490.	0.8	8
776	Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 109-126.	0.6	19
777	Biologics in bowel cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 449-456.	0.6	4
778	Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 985-989.	0.6	14
779	Regorafenib in gastric cancer. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 16-16.	1.5	2

#	ARTICLE	IF	CITATIONS
780	No benefit from ramucirumab in first-line chemotherapy?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 30-30.	1.5	2
781	Next generation sequencing identifies "interactome"™ signatures in relapsed and refractory metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 20-31.	0.6	14
782	Promising therapeutics of gastrointestinal cancers in clinical trials. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 524-533.	0.6	1
783	The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 29-29.	1.5	3
784	Targeting the microenvironment in solid tumors. <i>Cancer Treatment Reviews</i> , 2018, 65, 22-32.	3.4	342
785	Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2018, 17, 307-312.	1.0	23
786	Regorafenib-Associated Fatigue. <i>American Journal of Therapeutics</i> , 2018, 25, e715-e717.	0.5	0
787	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). <i>Oncology</i> , 2018, 94, 289-296.	0.9	5
788	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 838-848.	1.9	36
789	Resistance to Inhibitors of Angiogenesis. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 211-236.	0.1	2
790	Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820.	1.8	41
791	Novel approaches for molecular targeted therapy against hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 597-607.	1.8	58
792	Emerging Systemic Therapies for Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 179-191.	0.5	26
793	Which Side Effect Related to Chemotherapy Should Be Described to the Patients Before Treatment?. , 2018, , 349-354.		1
794	A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. <i>Cancer</i> , 2018, 124, 2337-2346.	2.0	47
795	The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients. <i>Journal of Oncological Science</i> , 2018, 4, 60-61.	0.1	1
796	<sc>FGFR</sc>2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers <i>in vitro</i>. <i>Molecular Oncology</i> , 2018, 12, 993-1003.	2.1	28
797	Disparities in Colon Cancer Survival by Insurance Type: A Population-Based Analysis. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 538-546.	0.7	33

#	ARTICLE	IF	CITATIONS
798	An Update on Colorectal Cancer. <i>Current Problems in Surgery</i> , 2018, 55, 76-116.	0.6	20
799	Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. <i>Annals of Oncology</i> , 2018, 29, 835-856.	0.6	53
800	Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis. <i>Future Oncology</i> , 2018, 14, 2905-2913.	1.1	10
801	Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 482-494.	0.8	67
802	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
803	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses. <i>JAMA Oncology</i> , 2018, 4, e175245.	3.4	98
804	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMOâ€ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2018, 29, 44-70.	0.6	432
805	The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. <i>Annals of Hematology</i> , 2018, 97, 839-849.	0.8	7
806	Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 195-206.	1.1	34
807	Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. <i>Cell Death and Differentiation</i> , 2018, 25, 616-633.	5.0	137
808	Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, e531-e539.	1.0	20
809	Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or synchronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial. <i>BMC Cancer</i> , 2018, 18, 297.	1.1	79
810	The importance of greater speed in drug development for advanced malignancies. <i>Cancer Medicine</i> , 2018, 7, 1824-1836.	1.3	23
811	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018, 69, 353-358.	1.8	270
814	Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2018, 105, 736-742.	0.1	55
815	Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 623-629.	0.9	6
816	A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e443-e449.	1.0	35
817	Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. <i>Methods in Molecular Biology</i> , 2018, 1765, 281-297.	0.4	12

#	ARTICLE	IF	CITATIONS
818	Anti-Angiogenics: Their Value in Colorectal Cancer Therapy. <i>Oncology Research and Treatment</i> , 2018, 41, 188-193.	0.8	35
819	Anti-Angiogenics: Current Situation and Future Perspectives. <i>Oncology Research and Treatment</i> , 2018, 41, 166-171.	0.8	164
820	Regorafenib in the treatment of metastatic colorectal cancer. <i>Future Oncology</i> , 2018, 14, 2239-2246.	1.1	14
821	Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs. <i>Clinical Colorectal Cancer</i> , 2018, 17, e381-e383.	1.0	3
822	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
823	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€™Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, e395-e414.	1.0	25
824	Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. <i>ESMO Open</i> , 2018, 3, e000297.	2.0	18
825	Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. <i>Cell Death and Disease</i> , 2018, 8, e2534-e2534.	2.7	72
826	Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and L-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 132-137.	0.6	7
827	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1-34.	1.0	1,187
828	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 25-34.	1.9	63
829	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 232-240.	3.0	40
830	Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. <i>Clinical Colorectal Cancer</i> , 2018, 17, e143-e151.	1.0	24
831	Clinical Features of Regorafenib-induced Liver Injury in Japanese Patients From Postmarketing Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, e49-e58.	1.0	17
832	Regorafenib Treatment for Management of Colorectal Cancer: A Systematic Review and Meta-analysis of 6 Randomized Controlled Trials. <i>American Journal of Therapeutics</i> , 2018, 25, e276-e278.	0.5	2
833	MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. <i>International Journal of Clinical Oncology</i> , 2018, 23, 281-286.	1.0	1
834	Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2018, 9, 15-23.	0.5	31
835	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. <i>Investigational New Drugs</i> , 2018, 36, 332-339.	1.2	52

#	ARTICLE	IF	CITATIONS
836	Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 470-475.	0.6	12
837	Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. <i>Oncologist</i> , 2018, 23, 7-15.	1.9	82
838	Neurological Complications of Targeted Therapies. , 2018, , 311-333.		2
839	Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer. <i>Case Reports in Oncology</i> , 2018, 10, 1029-1034.	0.3	6
840	Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM). <i>Annals of Surgical Oncology</i> , 2018, 25, 550-557.	0.7	14
841	Trifluridine+Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 285-288.	1.7	5
842	Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. <i>Medical Oncology</i> , 2018, 35, 4.	1.2	17
843	Systemic Therapy for Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 235-242.	0.6	113
844	A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2018, 17, 113-120.	1.0	59
845	Reactive oxygen species and colorectal cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 5119-5132.	2.0	105
846	Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 523-528.	0.9	3
847	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 316-325.	3.2	17
848	Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 62, 61-73.	3.4	47
849	Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. <i>Gastric Cancer</i> , 2018, 21, 473-480.	2.7	21
850	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. <i>Gut</i> , 2018, 67, 1484-1492.	6.1	59
851	A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer. <i>Medicine (United States)</i> , 2018, 97, e12635.	0.4	6
852	Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. <i>Anti-Cancer Drugs</i> , 2018, 29, 827-838.	0.7	9
853	Statistical and Clinical Significance in the TERRA Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1379-1380.	0.8	1

#	ARTICLE	IF	CITATIONS
854	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	0.6	192
855	Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation. <i>Medicine (United States)</i> , 2018, 97, e11178.	0.4	5
856	Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 350-358.	0.8	160
857	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	0.8	362
858	Reply to P. Di Nardo et al and R. Sun et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 1380-1381.	0.8	1
859	A simple and reliable ultra-high performance liquid chromatography coupled with tandem mass spectrometry method for simultaneous quantification of tyrosine and its metabolites in human urine. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2018, 41, 1013-1019.	0.5	2
860	Immunotherapy in colorectal cancer: for the select few or all?. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 170-179.	0.6	51
861	Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment. <i>Medicine (United States)</i> , 2018, 97, e13635.	0.4	12
862	Risk of regorafenib-induced cardiovascular events in patients with solid tumors. <i>Medicine (United States)</i> , 2018, 97, e13635.	0.4	14
863	Antiangiogenic Therapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 165-170.	1.0	77
864	Long Noncoding RNA XIST Regulates miR-137â€ZEH2 Axis to Promote Tumor Metastasis in Colorectal Cancer. <i>Oncology Research</i> , 2018, 27, 99-106.	0.6	56
865	Local Treatment Options for Unresectable Liver Metastases in Colorectal Cancer. , 0, , .		0
867	6 Colorectal Cancer. , 2018, , .		0
868	Cost-Effectiveness Analysis of Regorafenib for Third-line Metastatic Colorectal Cancer Compared to Cetuximab Plus Irinotecan in China. <i>Journal of Health &amp; Medical Economics</i> , 2018, 04, .	0.2	2
869	A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-6.	0.2	4
870	Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenibâ€”A cost-effectiveness analysis. <i>PLoS ONE</i> , 2018, 13, e0207132.	1.1	38
871	Treatment of Rectal Cancer in Older Adults. <i>Current Oncology Reports</i> , 2018, 20, 102.	1.8	3
872	Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer. <i>In Vivo</i> , 2018, 32, 1643-1646.	0.6	1

#	ARTICLE	IF	CITATIONS
873	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. <i>Nature Communications</i> , 2018, 9, 4672.	5.8	47
874	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 225-231.	1.0	4
875	Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	0.8	33
876	A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 6061-6070.	0.9	5
877	Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series. <i>Ecancermedalscience</i> , 2018, 12, 875.	0.6	1
878	Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6405-6414.	1.0	21
879	A comprehensive review of protein kinase inhibitors for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1249-1270.	1.1	164
880	Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2915.	1.8	10
881	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. <i>Journal of Hematology and Oncology</i> , 2018, 11, 120.	6.9	333
882	Drug resistance and new therapies in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3834-3848.	1.4	406
883	Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a thirdâ€line or later chemotherapy regimen for refractory metastatic colorectal cancer. <i>Oncology Letters</i> , 2018, 16, 6589-6597.	0.8	13
884	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
885	Functional Consequences and Clinical Significance of Tyrosine Kinase Inhibitors in Advanced Colorectal Cancer. , 2018, , 115-140.		0
886	Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 901-916.	1.9	7
887	Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 961-969.	1.1	20
888	Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2018, 38, 1109-1123.	1.1	16
889	Highly Sensitive Electrochemical Sensor for Anticancer Drug by a Zirconia Nanoparticle-Decorated Reduced Graphene Oxide Nanocomposite. <i>ACS Omega</i> , 2018, 3, 14597-14605.	1.6	68
890	Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges. <i>Clinics</i> , 2018, 73, e542s.	0.6	9



#	ARTICLE	IF	CITATIONS
892	Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 2915-2924.	0.9	9
893	Hypertension in malignancy-an underappreciated problem. <i>Oncotarget</i> , 2018, 9, 20855-20871.	0.8	18
894	Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 53-65.	2.0	12
895	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1451-1463.	0.9	5
896	Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 883-890.	1.0	5
897	Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCMA, c system in a quaternary oncology centre. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 865-876.	1.1	8
898	Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study. <i>Oncolmmunology</i> , 2018, 7, e1474319.	2.1	63
899	Down-Regulated LncRNA-HOTAIR Suppressed Colorectal Cancer Cell Proliferation, Invasion, and Migration by Mediating p21. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2320-2331.	1.1	34
900	Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1339-1346.	1.2	8
901	Metallic Stent for Malignant Colorectal Obstruction. <i>Digestive Disease Interventions</i> , 2018, 02, 046-052.	0.3	0
902	A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1193-1198.	0.6	21
903	Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models. <i>Angiogenesis</i> , 2018, 21, 793-804.	3.7	5
904	Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1090, 43-51.	1.2	16
905	Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. <i>Investigational New Drugs</i> , 2018, 36, 895-902.	1.2	1
906	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2486.	3.8	202
907	Regorafenib: A Review in Metastatic Colorectal Cancer. <i>Drugs</i> , 2018, 78, 1133-1144.	4.9	65
908	Transarterial Embolization with Small-Size Particles Loaded with Irinotecan for the Treatment of Colorectal Liver Metastases: Results of the MIRACLE III Study. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1708-1715.	0.9	14
909	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 258-273.	1.0	41

#	ARTICLE	IF	CITATIONS
910	Colon Cancer Chemoresistance and Chemosensitization. , 2018, , 181-226.		0
911	Growing Role of Regorafenib in the Treatment of Patients with Sarcoma. Targeted Oncology, 2018, 13, 417-422.	1.7	6
912	Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy. Medical Oncology, 2018, 35, 114.	1.2	3
913	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. Clinical Colorectal Cancer, 2018, 17, e719-e732.	1.0	10
914	<scp>ER</scp> stressâ€related <scp>ATF</scp>6 upregulates <scp>CIP</scp>2A and contributes to poor prognosis of colon cancer. Molecular Oncology, 2018, 12, 1706-1717.	2.1	44
915	Small Molecules in Oncology. Recent Results in Cancer Research, 2018, , .	1.8	5
916	New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer. International Journal of Medical Sciences, 2018, 15, 659-665.	1.1	59
917	The safety of ramucirumab for the treatment of colorectal cancer. Expert Opinion on Drug Safety, 2018, 17, 945-951.	1.0	14
918	Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a &ldquo;me too&rdquo; drug?. Cancer Management and Research, 2018, Volume 10, 425-437.	0.9	47
919	Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. Oncology Letters, 2018, 16, 3674-3680.	0.8	12
920	Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models. Journal of Cancer, 2018, 9, 1207-1217.	1.2	14
921	Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting. Neoplasma, 2018, 65, 599-603.	0.7	5
922	Regorafenib. Recent Results in Cancer Research, 2018, 211, 45-56.	1.8	100
923	Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. Frontiers in Oncology, 2018, 8, 226.	1.3	56
924	Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling. Journal of Experimental and Clinical Cancer Research, 2018, 37, 151.	3.5	26
925	Platelet-Derived Growth Factor Receptor (PDGF-R) as the Target for Herbal-Based Anticancer Agents. , 2018, , 411-427.		0
926	â€Vessels in the Stormâ€ Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 299.	1.8	29
927	The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. International Journal of Molecular Sciences, 2018, 19, 653.	1.8	29

#	ARTICLE	IF	CITATIONS
928	Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 1955-1963.	0.6	47
929	Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 991-1006.	1.1	44
930	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Critical Reviews in Oncology/Hematology, 2018, 130, 13-26.	2.0	34
931	Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Molecular Cancer Therapeutics, 2018, 17, 2112-2122.	1.9	33
932	Promising New Agents for Colorectal Cancer. Current Treatment Options in Oncology, 2018, 19, 29.	1.3	46
933	The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Expert Opinion on Drug Safety, 2018, 17, 643-650.	1.0	3
934	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. Future Oncology, 2018, 14, 2437-2459.	1.1	7
935	Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study. BMC Cancer, 2018, 18, 138.	1.1	6
936	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. Colorectal Cancer, 2018, 7, CRC01.	0.8	3
938	Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. Current Cancer Drug Targets, 2018, 18, 421-429.	0.8	50
939	Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer. OncoTargets and Therapy, 2018, Volume 11, 3059-3063.	1.0	13
940	Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer. OncoTargets and Therapy, 2018, Volume 11, 2467-2473.	1.0	12
941	Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. Clinical Colorectal Cancer, 2018, 17, e751-e761.	1.0	37
942	HER2: An emerging target in colorectal cancer. Current Problems in Cancer, 2018, 42, 560-571.	1.0	67
943	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. Journal of Cancer, 2018, 9, 2910-2915.	1.2	6
944	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. Clinical Cancer Research, 2018, 24, 6160-6167.	3.2	46
945	Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). Oncologist, 2018, 23, 1271.	1.9	11
946	Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Medicine, 2018, 7, 5382-5393.	1.3	32

#	ARTICLE	IF	CITATIONS
947	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e687-e697.	1.0	15
948	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	0.6	32
949	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: TheÂTOREADOR Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e601-e615.	1.0	18
950	Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018, 124, 3118-3126.	2.0	23
951	Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, 274-279.	1.0	17
952	Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study. <i>PLoS ONE</i> , 2018, 13, e0190497.	1.1	13
953	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 29-39.	2.3	43
954	Challenges of dispensing costly tablets with short shelf-life. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 210-213.	0.5	1
955	Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 601-603.	0.6	5
956	Multiple treatment lines and prognosis in metastatic colorectal cancer patients. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 307-313.	2.7	38
957	SIR-Spheres<sup>Â®</sup> Y-90 resin microspheres in chemotherapy refractory or intolerant patients with metastatic colorectal cancer. <i>Global &amp; Regional Health Technology Assessment</i> , 2019, 2019, 228424031984744.	0.2	1
958	<p>Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 199-219.	0.7	1
959	Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 4139-4147.	2.0	299
960	Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 83.	1.3	21
961	Monitoring treatment response in metastatic colorectal cancer: Economic evaluation of PrediCTC versus computed tomography scan. <i>Global &amp; Regional Health Technology Assessment</i> , 2019, 2019, 228424031985833.	0.2	1
962	ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. <i>Clinical Colorectal Cancer</i> , 2019, 18, 280-291.e5.	1.0	16
963	Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2019, 51, 1357-1363.	0.4	80
964	Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 899-905.	1.4	0

#	ARTICLE	IF	CITATIONS
965	Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004-2015. <i>Cancer</i> , 2019, 125, 3828-3835.	2.0	74
966	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019, 9, 622.	1.3	22
967	Liver-Directed and Systemic Therapies for Colorectal Cancer Liver Metastases. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1240-1254.	0.9	7
968	Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes. <i>Cancers</i> , 2019, 11, 983.	1.7	14
969	Colorectal cancer in adolescents and young adults: Defining a growing threat. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27941.	0.8	29
970	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e349-e360.	1.0	31
971	Regorafenib Prior to Selective Internal Radiation Therapy Using 90Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety, Dosimetry, and Molecular Markers. <i>Frontiers in Oncology</i> , 2019, 9, 624.	1.3	6
973	A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 378-383.	2.9	2
974	Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 861.	1.7	25
975	Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trial. <i>Lancet Oncology</i> , The, 2019, 20, 1036-1037.	5.1	8
976	Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands. <i>Oncology Research</i> , 2019, 27, 551-556.	0.6	7
977	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1070-1082.	5.1	169
978	Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1213-1220.	0.9	10
980	Integrated Analysis of the Gene Expression Changes During Colorectal Cancer Progression by Bioinformatic Methods. <i>Journal of Computational Biology</i> , 2019, 26, 1168-1176.	0.8	17
981	A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2313-2323.	1.2	11
982	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
983	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3021-3036.	1.2	20
984	Socio-economic drivers of pig production and their effects on achieving sustainable development goals in China. <i>Journal of Integrative Environmental Sciences</i> , 2019, 16, 141-155.	1.0	19

#	ARTICLE	IF	CITATIONS
985	Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis. <i>Value in Health</i> , 2019, 22, 1370-1377.	0.1	18
986	Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer. <i>Cytokine and Growth Factor Reviews</i> , 2019, 49, 1-9.	3.2	11
987	NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1649.	1.7	17
988	A gene-based anti-angiogenesis therapy as a novel strategy for cancer treatment. <i>Life Sciences</i> , 2019, 239, 117018.	2.0	9
989	A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1032.	1.1	9
990	Glasgow Prognostic Score as a Predictor of Bevacizumab Efficacy in the First-line Treatment with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 6858-6864.	1.2	3
991	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. <i>European Journal of Cancer</i> , 2019, 123, 146-154.	1.3	46
992	Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101912.	3.4	109
993	Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. <i>Pharmacological Research</i> , 2019, 150, 104511.	3.1	300
994	Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial $\beta$ -Glucuronidases. <i>ACS Chemical Biology</i> , 2019, 14, 2737-2744.	1.6	41
995	Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. , 2019, 7, 297.		24
996	&lt;p&gt;Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer&lt;/p&gt; Patient Preference and Adherence, 2019, Volume 13, 1745-1750.	0.8	10
997	Real-World Use of Trifluridine/Tipiracil for Patients with Metastatic Colorectal Cancer in Canada. <i>Current Oncology</i> , 2019, 26, 319-329.	0.9	9
998	Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. <i>Journal of Cancer</i> , 2019, 10, 4671-4678.	1.2	7
999	The clinical conundrum of managing 5-Fluorouracil-induced vasospasm in colorectal carcinoma. <i>Cancer</i> , 2019, 125, 4346-4349.	2.0	3
1000	Colorectal cancer. <i>Lancet, The</i> , 2019, 394, 1467-1480.	6.3	2,462
1001	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
1002	A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 422.	3.5	23

#	ARTICLE	IF	CITATIONS
1003	A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 909-917.	1.1	13
1004	Precision medicine for metastatic colorectal cancer: an evolving era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 919-931.	1.4	34
1005	Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2019, 11, 390-396.	0.4	5
1006	Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 370-377.	0.7	4
1007	Fruquintinib and its use in the treatment of metastatic colorectal cancer. <i>Future Oncology</i> , 2019, 15, 2571-2576.	1.1	9
1008	Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. <i>Frontiers in Oncology</i> , 2019, 9, 766.	1.3	18
1009	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. <i>Clinical Colorectal Cancer</i> , 2019, 18, 307-309.	1.0	6
1010	A positive feedback loop of $\beta$ -catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer. <i>Cell Death and Disease</i> , 2019, 10, 643.	2.7	28
1011	Fruquintinib: a novel antivasular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 7787-7803.	0.9	33
1012	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. <i>Clinical Colorectal Cancer</i> , 2019, 18, 269-279.e5.	1.0	4
1013	Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-15.	3.2	52
1014	Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies. , 2019, , .		3
1015	Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study. <i>Targeted Oncology</i> , 2019, 14, 689-697.	1.7	7
1016	Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987619.	1.4	0
1017	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. <i>Pharmacogenomics Journal</i> , 2019, 19, 455-464.	0.9	5
1018	Angiogenesis in 90Y-Radioembolization of Colorectal Liver Metastases. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 204-210.	2.5	5
1019	Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 1110-1117.	0.7	7
1020	Long noncoding RNA GAS5 inhibits angiogenesis and metastasis of colorectal cancer through the Wnt/ $\beta$ -catenin signaling pathway. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 6937-6951.	1.2	49

#	ARTICLE	IF	CITATIONS
1021	Treatment sequencing in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019, 109, 70-83.	1.3	215
1022	Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491882544.	0.6	17
1023	S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. <i>Oncologist</i> , 2019, 24, 591-e165.	1.9	11
1024	Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report. <i>BMC Cancer</i> , 2019, 19, 567.	1.1	15
1025	Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers. <i>Advances in Therapy</i> , 2019, 36, 1986-1998.	1.3	7
1026	Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. <i>Clinical and Translational Oncology</i> , 2019, 21, 1781-1785.	1.2	9
1027	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. <i>Journal of Controlled Release</i> , 2019, 307, 108-138.	4.8	49
1028	Maximising clinical benefit with adequate patient management beyond the second line in mCRC. <i>ESMO Open</i> , 2019, 4, e000495.	2.0	14
1029	Cardiovascular complications of metastatic colorectal cancer treatment. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 797-806.	0.6	13
1030	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. <i>Cancer Research</i> , 2019, 79, 4196-4210.	0.4	53
1031	<i>KIT</i> mutation in a naïve succinate dehydrogenase-deficient gastric GIST. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 798-803.	1.5	7
1032	Systemic steroid treatment can desensitize the skin reaction due to regorafenib in a recurrence colorectal cancer patient. <i>International Cancer Conference Journal</i> , 2019, 8, 164-169.	0.2	4
1033	First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). <i>BMC Cancer</i> , 2019, 19, 533.	1.1	10
1034	The clinical application of fruquintinib on colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 713-721.	1.3	14
1035	Role of Hepatic Artery Infusion Chemotherapy in Treatment of Initially Unresectable Colorectal Liver Metastases. <i>JAMA Surgery</i> , 2019, 154, 768.	2.2	84
1036	Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. <i>Cancer Letters</i> , 2019, 460, 1-9.	3.2	156
1037	Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 412-420.	0.6	6
1038	Colorectal Cancer Research: A State of the Art. <i>Hot Topics in Acute Care Surgery and Trauma</i> , 2019, , 1-13.	0.1	1



#	ARTICLE	IF	CITATIONS
1039	A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. <i>Science Advances</i> , 2019, 5, eaav6528.	4.7	74
1040	Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 20-28.	3.4	159
1041	Systemic Therapy for Advanced and Metastatic Colon Cancer. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 73, 202.	0.2	1
1042	Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 159-166.e3.	1.0	14
1043	Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis. <i>Neuro-Oncology</i> , 2019, 21, 954-955.	0.6	15
1044	Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 295-306.	1.7	5
1045	Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 411-418.	0.8	16
1046	What Is a Clinically Meaningful Survival Benefit in Refractory Metastatic Colorectal Cancer?. <i>Current Oncology</i> , 2019, 26, 255-259.	0.9	5
1047	<sup>3</sup> â€²-Deoxy- <sup>3</sup> â€™-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1713-1722.	3.3	8
1048	Basket Trials for Intractable Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 229.	1.3	22
1049	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
1050	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2019, 20, 849-861.	5.1	368
1051	&lt;p&gt;Selecting treatment options in refractory metastatic colorectal cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2271-2278.	1.0	20
1052	Inflammationâ€and angiogenesisâ€related biomarkers are correlated with cancerâ€related fatigue in colorectal cancer patients: Results from the ColoCare Study. <i>European Journal of Cancer Care</i> , 2019, 28, e13055.	0.7	26
1053	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1424-1431.	0.8	172
1054	Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles. <i>Cancers</i> , 2019, 11, 571.	1.7	25
1055	Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 355-360.	0.4	7
1056	A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 883-e407.	1.9	43

#	ARTICLE	IF	CITATIONS
1057	Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2173-2179.	1.6	7
1058	Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 5-13.	0.7	6
1059	Evidence-Based Integration of Yttrium-90 Radioembolization in the Contemporary Management of Hepatic Metastases from Colorectal Cancer. <i>Techniques in Vascular and Interventional Radiology</i> , 2019, 22, 74-80.	0.4	7
1060	Early experience with Watson for oncology in Korean patients with colorectal cancer. <i>PLoS ONE</i> , 2019, 14, e0213640.	1.1	26
1061	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	1.2	7
1062	A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 411-417.	1.1	4
1063	Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 809-815.	1.1	16
1064	Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies. <i>Cancer Management and Research</i> , 2019, Volume 11, 1705-1716.	0.9	22
1065	Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib. <i>Clinical and Translational Oncology</i> , 2019, 21, 1518-1523.	1.2	18
1066	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 27.	6.9	211
1067	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019, 145, 2450-2458.	2.3	5
1068	Acute abdominal obstruction: Colon stent or emergency surgery? An evidence-based review. <i>World Journal of Gastrointestinal Endoscopy</i> , 2019, 11, 193-208.	0.4	31
1069	Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. <i>Drugs</i> , 2019, 79, 633-645.	4.9	32
1070	Ramucirumab: the long and winding road toward being an option for mCRC treatment. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 399-409.	1.4	6
1071	Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC). <i>Frontiers in Oncology</i> , 2019, 9, 142.	1.3	6
1072	RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 957-968.	1.9	32
1073	Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 343-353.	1.1	16
1074	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019, 119, 564-582.	0.8	55

#	ARTICLE	IF	CITATIONS
1075	Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer. <i>Oncology</i> , 2019, 96, 200-206.	0.9	17
1076	Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials. <i>BMC Cancer</i> , 2019, 19, 134.	1.1	61
1077	Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma. <i>Bangladesh Journal of Pharmacology</i> , 2019, 14, 32-35.	0.1	0
1078	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. <i>Clinical Colorectal Cancer</i> , 2019, 18, 125-132.e2.	1.0	35
1079	Plasma HER2 ( <i>ERBB2</i> ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3046-3053.	3.2	112
1080	Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREATME1 trial. <i>International Journal of Cancer</i> , 2019, 145, 1538-1546.	2.3	55
1081	Precision treatment in colorectal cancer: Now and the future. <i>JGH Open</i> , 2019, 3, 361-369.	0.7	36
1082	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 469-493.	12.5	285
1083	Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients. , 0, , .		0
1084	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000813.	2.0	49
1085	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000519.	2.0	5
1086	Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. <i>Oncologist</i> , 2019, 24, e450-e457.	1.9	28
1087	Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?. <i>Translational Lung Cancer Research</i> , 2019, 8, 319-322.	1.3	6
1088	Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial. <i>Oncologist</i> , 2019, 24, 1180-1187.	1.9	19
1089	Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000584.	2.0	7
1090	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). <i>Future Oncology</i> , 2019, 15, 4009-4017.	1.1	8
1091	Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2379-2383.	0.2	7
1092	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	1.8	34

#	ARTICLE	IF	CITATIONS
1093	Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 2031.	1.0	23
1094	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. <i>Frontiers in Oncology</i> , 2019, 9, 1102.	1.3	15
1095	Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib. <i>Cancers</i> , 2019, 11, 1878.	1.7	13
1096	Naples Prognostic Score Is a Useful Prognostic Marker in Patients With Metastatic Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1485-1493.	0.7	39
1097	Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1253.	1.1	26
1098	Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1 genotyping in previous treated metastatic colorectal cancer patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 751.	0.7	5
1099	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
1100	Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. <i>PLoS ONE</i> , 2019, 14, e0225938.	1.1	18
1101	Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. <i>Current Oncology</i> , 2019, 26, 24-32.	0.9	11
1102	Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond. <i>Current Oncology</i> , 2019, 26, 33-42.	0.9	7
1103	RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. <i>Cancer Imaging</i> , 2019, 19, 85.	1.2	9
1104	A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1174-1179.	1.9	14
1105	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019, 24, 185-192.	1.9	89
1106	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , 2019, 73, 41-53.	3.4	69
1107	Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. <i>Biomedicine and Pharmacotherapy</i> , 2019, 110, 775-785.	2.5	170
1108	A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. <i>Cancer</i> , 2019, 125, 902-909.	2.0	98
1109	Recent Advances in the Treatment of Colorectal Cancer. , 2019, , .		2
1110	Chemotherapy for Metastatic Colorectal Cancer. , 2019, , 101-111.		1

#	ARTICLE	IF	CITATIONS
1111	Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1456-1461.	2.3	17
1112	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 46-54.	1.2	40
1113	Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 42-47.	0.6	25
1114	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	1.0	53
1115	Current status of immunotherapy in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 13-25.	1.0	106
1116	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 120-133.	5.1	222
1117	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	3.4	280
1118	Associations among regorafenib concentrations, severe adverse reactions, and <i>ABCG2</i> and <i>OATP1B1</i> polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 107-113.	1.1	7
1119	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. <i>Drug Safety</i> , 2019, 42, 159-179.	1.4	18
1120	Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. <i>Translational Oncology</i> , 2019, 12, 502-512.	1.7	14
1121	Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 133-142.	0.6	10
1122	Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer. <i>Digestion</i> , 2019, 99, 79-85.	1.2	3
1123	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 697-706.	0.8	3
1124	Targeting Angiogenesis in Colorectal Carcinoma. <i>Drugs</i> , 2019, 79, 63-74.	4.9	42
1125	Texture in the monitoring of regorafenib therapy in patients with colorectal liver metastases. <i>Acta Radiologica</i> , 2019, 60, 1084-1093.	0.5	27
1126	Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 278-289.	2.0	24
1127	Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 5601-5612.	2.0	7
1128	Suppression of interferon gene expression overcomes resistance to MEK inhibition in <i>KRAS</i> -mutant colorectal cancer. <i>Oncogene</i> , 2019, 38, 1717-1733.	2.6	29

#	ARTICLE	IF	CITATIONS
1129	Medical oncologists must get more involved in systemic treatment. <i>Annals of Oncology</i> , 2019, 30, 6-8.	0.6	2
1130	Strategies for targeting energy metabolism in Kirsten rat sarcoma viral oncogene homolog $\mu$ mutant colorectal cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1106-1121.	1.2	0
1131	Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 115-122.	1.1	14
1132	Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials. <i>Investigational New Drugs</i> , 2019, 37, 490-497.	1.2	4
1133	Predictive Biomarkers and Targeted Therapies in Colorectal Cancer. , 2019, , 423-430.		2
1134	Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 725-736.	1.2	51
1135	HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 29-38.	1.9	32
1136	REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2019, 30, 259-265.	0.6	56
1137	Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic colorectal cancer treated with regorafenib. <i>Acta Radiologica</i> , 2019, 60, 836-845.	0.5	2
1138	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 110-119.	5.1	238
1139	Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. <i>Cancer Biology and Therapy</i> , 2019, 20, 391-396.	1.5	9
1140	Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 16-22.	0.6	5
1141	Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 69-77.	0.6	16
1142	Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. <i>Seminars in Cancer Biology</i> , 2019, 56, 87-99.	4.3	33
1143	DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. <i>Future Oncology</i> , 2019, 15, 2349-2360.	1.1	9
1144	Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. <i>Clinical and Translational Oncology</i> , 2020, 22, 351-359.	1.2	14
1145	Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 254-263.	0.6	19
1146	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1-42.	1.0	1,123

#	ARTICLE	IF	CITATIONS
1147	HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. <i>Cancer Gene Therapy</i> , 2020, 27, 341-355.	2.2	61
1148	Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a. <i>Investigational New Drugs</i> , 2020, 38, 229-245.	1.2	42
1149	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. <i>Investigational New Drugs</i> , 2020, 38, 111-119.	1.2	6
1150	Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. <i>Autophagy</i> , 2020, 16, 106-122.	4.3	91
1151	HER2-targeted therapies â€” a role beyond breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 33-48.	12.5	569
1152	Risk of hand-foot skin reaction associated with vascular endothelial growth factorâ€”tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 788-796.	0.6	21
1153	DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer. <i>Carcinogenesis</i> , 2020, 41, 303-312.	1.3	20
1154	Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. <i>Annals of Palliative Medicine</i> , 2020, 9, 1296-1306.	0.5	5
1155	The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 15-22.	1.4	16
1156	Risk factors and prognostic significance of lateral pelvic lymph node metastasis in advanced rectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 110-117.	1.0	13
1157	Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 387-400.	0.6	6
1158	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
1159	Deep Learning Enhancing Kinome-Wide Polypharmacology Profiling: Model Construction and Experiment Validation. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8723-8737.	2.9	58
1160	Feasibility and Safety of CT-Guided High-Dose-Rate Brachytherapy Combined with Transarterial Chemoembolization Using Irinotecan-Loaded Microspheres for the Treatment of Large, Unresectable Colorectal Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 315-322.	0.2	6
1161	Principles of Targeted Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 175-188.	0.5	40
1162	A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposureâ€”Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). <i>Clinical Colorectal Cancer</i> , 2020, 19, 13-21.e3.	1.0	17
1163	Basics to advances in nanotherapy of colorectal cancer. <i>Drug Delivery and Translational Research</i> , 2020, 10, 319-338.	3.0	24
1164	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2020, 19, 39-47.e5.	1.0	9

#	ARTICLE	IF	CITATIONS
1165	Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis. <i>American Journal of Transplantation</i> , 2020, 20, 530-537.	2.6	62
1166	Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 223-228.	1.0	4
1167	Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. <i>Oncologist</i> , 2020, 25, e75-e84.	1.9	14
1168	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. <i>Acta OncolÃ³gica</i> , 2020, 59, 417-426.	0.8	22
1169	Vessel co-option and resistance to anti-angiogenic therapy. <i>Angiogenesis</i> , 2020, 23, 55-74.	3.7	77
1170	Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. <i>Frontiers of Medicine</i> , 2020, 14, 273-283.	1.5	9
1171	Immune stimulatory effect of anti-EpCAM immunotoxin â€œ improved overall survival of metastatic colorectal cancer patients. <i>Acta OncolÃ³gica</i> , 2020, 59, 404-409.	0.8	9
1172	Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis. <i>Journal of Chemotherapy</i> , 2020, 32, 41-48.	0.7	1
1173	Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 36.	1.7	58
1174	Regorafenib, TAS-102, or fruqintinib for metastatic colorectal cancer: any difference in randomized trials?. <i>International Journal of Colorectal Disease</i> , 2020, 35, 295-306.	1.0	11
1175	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <scp>CONCUR</scp> trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1307-1316.	1.4	8
1176	Targeted cancer therapies (biologics). , 2020, , 154-165.e4.		0
1177	Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 614-621.	1.0	13
1178	Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities. <i>International Journal of Clinical Oncology</i> , 2020, 25, 531-540.	1.0	13
1179	Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. <i>Annals of Surgery</i> , 2020, 271, 212-218.	2.1	190
1180	Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 28-34.	0.6	8
1181	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. <i>Targeted Oncology</i> , 2020, 15, 67-73.	1.7	1
1182	Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. <i>Oncologist</i> , 2020, 25, e469-e476.	1.9	20



#	ARTICLE	IF	CITATIONS
1184	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 82, 101935.	3.4	17
1186	Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer. <i>Case Reports in Oncology</i> , 2020, 12, 791-795.	0.3	3
1187	Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial. <i>Cancers</i> , 2020, 12, 2752.	1.7	3
1188	Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy. <i>Cancers</i> , 2020, 12, 2812.	1.7	3
1189	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 755-769.	1.0	9
1190	&lt;p&gt;Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10197-10206.	1.0	7
1191	An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. , 2020, , 1-27.		0
1192	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0239439.	1.1	5
1193	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	0.6	5
1194	Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. <i>Annals of Oncology</i> , 2020, 31, 1169-1177.	0.6	70
1195	Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188447.	3.3	97
1196	The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs. <i>Science Advances</i> , 2020, 6, .	4.7	7
1197	Optimized lowâ€dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. <i>Molecular Oncology</i> , 2020, 14, 2894-2919.	2.1	20
1198	Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093693.	1.4	71
1199	Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy. , 2020, , .		2
1200	Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. <i>Gastroenterology Report</i> , 2020, 8, 179-191.	0.6	60
1201	A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer. <i>Journal of International Medical Research</i> , 2020, 48, 030006052092640.	0.4	2
1202	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1875.	1.7	19

#	ARTICLE	IF	CITATIONS
1203	MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 311-318.e1.	1.0	4
1204	BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. <i>Gastroenterology Report</i> , 2020, 8, 192-205.	0.6	59
1205	Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1143-1157.	2.7	19
1207	Tyrosine Kinase Receptors in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8529.	1.8	46
1208	Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 475-485.	1.5	7
1209	A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. <i>Cell Death and Disease</i> , 2020, 11, 982.	2.7	1
1210	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095686.	1.4	16
1211	Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 590707.	1.3	14
1212	Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment. <i>Cancers</i> , 2020, 12, 3481.	1.7	9
1213	The Role of BRAF in Metastatic Colorectal Carcinoma—Past, Present, and Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9001.	1.8	8
1214	Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 587692.	1.3	3
1215	Quality of Life in a Real-World Study of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil. <i>Current Oncology</i> , 2020, 27, 451-458.	0.9	10
1216	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 137, 117-126.	1.3	16
1217	Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review. <i>Advances in Therapy</i> , 2020, 37, 4233-4248.	1.3	5
1218	Development of Promitil® <sup>®</sup> , a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside. <i>Advanced Drug Delivery Reviews</i> , 2020, 154-155, 13-26.	6.6	28
1219	Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. <i>Cancer Management and Research</i> , 2020, Volume 12, 5819-5830.	0.9	8
1220	Mcl-1 inhibition overcomes intrinsic and acquired Regorafenib resistance in Colorectal Cancer. <i>Theranostics</i> , 2020, 10, 8098-8110.	4.6	45
1221	Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094093.	1.4	4

#	ARTICLE	IF	CITATIONS
1222	Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2575-2587.	1.2	19
1223	REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancer. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 423-430.	1.0	3
1224	Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22780.	0.4	4
1225	Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China. <i>BMC Cancer</i> , 2020, 20, 990.	1.1	8
1226	A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. <i>Journal of Medical Economics</i> , 2020, 23, 1588-1597.	1.0	6
1227	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , 2020, 91, 102112.	3.4	29
1228	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	6.9	226
1229	Hydrocolloid dressing as a prophylactic use for hand–foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study. <i>BMJ Open</i> , 2020, 10, e038276.	0.8	3
1230	KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
1231	Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503). <i>ESMO Open</i> , 2020, 5, e000776.	2.0	11
1232	Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. <i>British Journal of Cancer</i> , 2020, 123, 1490-1495.	2.9	30
1233	Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094324.	0.8	1
1234	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. <i>Advances in Therapy</i> , 2020, 37, 4585-4598.	1.3	8
1235	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2146-2154.	1.9	18
1236	Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. <i>Cancer Management and Research</i> , 2020, Volume 12, 5365-5372.	0.9	8
1237	Interstitial Brachytherapy for Limited (<4 cm) and Large (≥4 cm) Hepatic Metastases from Rare and Less Common Cancers. <i>Anticancer Research</i> , 2020, 40, 4281-4289.	0.5	4
1238	Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. <i>Cancers</i> , 2020, 12, 3746.	1.7	6
1239	Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 4015.	1.0	7

#	ARTICLE	IF	CITATIONS
1240	The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 594125.	1.3	23
1241	Small bowel wall edema induced by regorafenib is associated with regorafenib intolerance and shorter survival in patients with metastatic colorectal cancer: A retrospective study. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097847.	0.5	1
1242	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	8
1243	Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitorsâ€”2020 Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 3520.	1.0	16
1244	Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2362-2376.	1.1	19
1245	Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer. <i>Tumori</i> , 2020, 106, 400-405.	0.6	3
1246	Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 â€” REGOLD. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1255-1262.	0.5	12
1247	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1214.	1.7	26
1248	First-In-Human Phase 1 Clinical Trials â€” A Single-Center Experience In The Era Of Modern Oncotherapeutics. <i>Scientific Reports</i> , 2020, 10, 7935.	1.6	5
1249	Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 831.	3.4	221
1250	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. <i>Cancer Medicine</i> , 2020, 9, 5035-5050.	1.3	8
1251	Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models. <i>Translational Oncology</i> , 2020, 13, 100793.	1.7	4
1252	Tumor Endothelial Cellâ€”A Biological Tool for Translational Cancer Research. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3238.	1.8	22
1253	A multiâ€”institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. <i>Cancer</i> , 2020, 126, 3464-3470.	2.0	24
1254	Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study. <i>Clinical Colorectal Cancer</i> , 2020, 19, e208-e225.	1.0	13
1255	Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3686.	1.8	20
1256	Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan. <i>PLoS ONE</i> , 2020, 15, e0234314.	1.1	11
1257	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , 2020, 19, 285-290.	1.0	5

#	ARTICLE	IF	CITATIONS
1258	Liver segment 2+3 living donation in liver transplantation for colorectal liver metastases. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 382-384.	0.7	2
1259	Authors' Reply to Yusuf Ziya Sener: Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study. <i>Targeted Oncology</i> , 2020, 15, 413-414.	1.7	0
1261	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. <i>ESMO Open</i> , 2020, 5, e000698.	2.0	26
1262	Phase I Study of Alternate-Day Administration of 1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1614-e1620.	1.9	0
1263	Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1772.	1.0	3
1264	Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. <i>Oncologist</i> , 2020, 25, e1628-e1639.	1.9	4
1265	Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. <i>BMJ Open</i> , 2020, 10, e027665.	0.8	7
1266	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020, 19, 165-177.	1.0	15
1267	Advances in immunotherapy for colorectal cancer: a review. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482091752.	1.4	139
1268	Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 128, 110319.	2.5	23
1269	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4478-4484.	3.2	20
1270	Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 425.	1.8	28
1271	Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2077-2087.	1.2	10
1272	Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland. <i>Oncology Research and Treatment</i> , 2020, 43, 237-244.	0.8	3
1273	"The same old story": thoughts on authorized doses of anticancer drugs. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090541.	1.4	5
1274	Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 739-751.	4.3	9
1275	Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2020, 40, 1605-1611.	0.5	3
1276	Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era. <i>International Journal of Cancer</i> , 2020, 147, 1778-1792.	2.3	21

#	ARTICLE	IF	CITATIONS
1277	Development of Dual-Scale Fluorescence Endoscopy for In Vivo Bacteria Imaging in an Orthotopic Mouse Colon Tumor Model. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 844.	1.3	4
1278	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
1279	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270.	1.1	4
1280	Long Non-coding RNA MIR570MC Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling. <i>Frontiers in Oncology</i> , 2020, 10, 291.	1.3	6
1281	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 82-90.e9.	1.0	6
1282	Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091091.	1.4	12
1283	Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i> -Mutated Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1148-1156.	1.9	22
1284	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853
1285	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , 2020, 395, 1078-1088.	6.3	302
1286	Immunogenic cell death in colon cancer prevention and therapy. <i>Molecular Carcinogenesis</i> , 2020, 59, 783-793.	1.3	65
1287	Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. <i>Cancers</i> , 2020, 12, 731.	1.7	280
1288	Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28222.	0.8	8
1289	Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil for Patients with Unresectable Liver Metastases from Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter Retrospective Study. <i>Oncology</i> , 2020, 98, 267-272.	0.9	4
1290	Activity of regorafenib in advanced pretreated soft tissue sarcoma. <i>Medicine (United States)</i> , 2020, 99, e20719.	0.4	10
1291	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	1.0	56
1292	Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603). <i>Oncology</i> , 2020, 98, 719-726.	0.9	0
1293	Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. <i>Clinical Therapeutics</i> , 2020, 42, 1376-1387.	1.1	5
1294	Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 823-835.	1.5	12

#	ARTICLE	IF	CITATIONS
1295	Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 586-595.	2.3	13
1296	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. <i>Cancer Science</i> , 2020, 111, 441-450.	1.7	8
1297	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. <i>Journal of Translational Medicine</i> , 2020, 18, 99.	1.8	12
1298	Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials. <i>Journal of Chemotherapy</i> , 2020, 32, 163-170.	0.7	3
1299	Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 311-320.	1.3	16
1300	Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study. <i>Journal of Leukocyte Biology</i> , 2020, 108, 715-721.	1.5	11
1301	Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. <i>Cancer Control</i> , 2020, 27, 107327482090227.	0.7	8
1302	Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data. <i>Gastric Cancer</i> , 2020, 23, 627-638.	2.7	8
1303	BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors. <i>BMC Cancer</i> , 2020, 20, 129.	1.1	9
1304	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020, 86, 101993.	3.4	61
1305	Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculation. <i>Pharmaceutical Statistics</i> , 2020, 19, 126-136.	0.7	0
1306	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020, 25, e68-e74.	1.9	10
1307	Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer. <i>Cancers</i> , 2020, 12, 414.	1.7	2
1308	Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression. <i>Clinical and Translational Oncology</i> , 2020, 22, 1491-1498.	1.2	16
1309	Pembrolizumab for the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 219-226.	1.4	21
1310	Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2020, 38, 1411-1420.	1.2	14
1311	TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 412-420.	5.1	140
1312	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102877.	2.0	14

#	ARTICLE	IF	CITATIONS
1313	CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. <i>Cells</i> , 2020, 9, 124.	1.8	5
1314	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <i>BioMed Research International</i> , 2020, 2020, 1-24.	0.9	38
1315	A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 593-604.	1.1	36
1316	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). <i>Journal of Clinical Oncology</i> , 2020, 38, 2053-2061.	0.8	469
1317	Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 3-12.	0.7	1
1318	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 783-794.	1.0	7
1319	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 86, 102020.	3.4	9
1320	Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study. <i>Scientific Reports</i> , 2020, 10, 6058.	1.6	22
1321	Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000634.	2.0	20
1322	GALC Triggers Tumorigenicity of Colorectal Cancer via Senescent Fibroblasts. <i>Frontiers in Oncology</i> , 2020, 10, 380.	1.3	10
1323	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020, 38, 683-713.	1.7	10
1324	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	1.0	20
1325	Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3557-3564.	3.2	4
1326	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. <i>Clinical Cancer Research</i> , 2020, 26, 4107-4119.	3.2	68
1327	Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1555-1562.	3.2	10
1328	Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit. <i>World Journal of Surgical Oncology</i> , 2020, 18, 65.	0.8	0
1329	Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. <i>Current Medical Research and Opinion</i> , 2021, 37, 59-70.	0.9	5
1330	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. <i>Neuro-Oncology</i> , 2021, 23, 264-276.	0.6	48



#	ARTICLE	IF	CITATIONS
1331	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190.	2.9	7
1332	Curcumin: A therapeutic strategy for colorectal cancer?. <i>Seminars in Cancer Biology</i> , 2021, 73, 321-330.	4.3	31
1333	First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, e43-e52.	1.0	5
1334	An appraisal of emerging second line therapies for metastatic colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 165-179.	1.4	2
1335	Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 111-117.	1.0	21
1336	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
1337	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
1339	FMS-like tyrosine kinase 3 ( FLT3 ) amplification in patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 314-322.	1.7	8
1340	Arterial Embolization Using Microspheres for Hypervascular Liver Metastases Refractory to Standard Treatments: A Multicenter Prospective Clinical Trial. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 392-400.	0.9	5
1341	Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib. <i>International Journal of Clinical Oncology</i> , 2021, 26, 409-416.	1.0	8
1342	Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?. <i>Current Problems in Cancer</i> , 2021, 45, 100670.	1.0	2
1343	Association Between Use of Anticancer Drugs and Cardiovascular Disease-Related Hospitalization in Metastatic Colorectal Cancer: Insights From a Population-Based Study, the Anticancer Vigilance of Cardiac Events Study. <i>American Journal of Epidemiology</i> , 2021, 190, 376-385.	1.6	1
1344	Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 217-233.	1.4	37
1345	Metabonomics study on orthotopic transplantation mice model of colon cancer treated with <i>Astragalus membranaceus</i> - <i>Curcuma wenyujin</i> in different proportions via UPLC-Q-TOF/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 193, 113708.	1.4	24
1346	Controversies in the treatment of RAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 827-839.	1.2	3
1347	Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 784-787.	0.6	0
1348	Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real-world multi-institution cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 84-93.	0.7	7
1349	Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 131-139.	1.0	3

#	ARTICLE	IF	CITATIONS
1350	C�ancer colorrectal. <i>Medicine</i> , 2021, 13, 1335-1344.	0.0	1
1351	Tolerance and Efficacy of Regorafenib according to UGT Pharmacogenetical Status in the Treatment of Metastatic Refractory Colorectal Cancer. <i>Oncologie</i> , 2021, 23, 195-202.	0.2	1
1352	Experience with regorafenib in the treatment of hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110169.	1.4	74
1353	Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib. <i>Anticancer Research</i> , 2021, 41, 567-582.	0.5	11
1354	Intraarterial Chemotherapy for Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 143-158.	0.6	5
1355	Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 2023-2031.	0.8	4
1356	Safety and tolerability of regorafenib: a real-life experience. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 187-191.	0.6	4
1357	Oral drugs in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110090.	1.4	31
1358	Retreatment of Irinotecan in Later Lines of Therapy for Metastatic Colorectal Cancer: A Retrospective Study. <i>Oncology</i> , 2021, 99, 665-672.	0.9	1
1359	Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2033441.	2.8	4
1360	Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China. <i>Journal of Medical Economics</i> , 2021, 24, 339-344.	1.0	8
1361	Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2139-2147.	3.2	77
1362	Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis. , 2021, , 239-253.		0
1363	Metformin plus Irinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial. <i>British Journal of Cancer</i> , 2021, 124, 1072-1078.	2.9	17
1364	The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand�Foot Skin Reaction. <i>Cancer Management and Research</i> , 2021, Volume 13, 45-53.	0.9	2
1365	A prospective phase II study of raltitrexed combined with S�1 as salvage treatment for patients with refractory metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 513-521.	0.7	4
1366	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. <i>Cancer Discovery</i> , 2021, 11, 1716-1735.	7.7	30
1367	Advances in the Relationship Between Regulator of Ribosome Synthesis 1 (RRS1) and Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 620925.	1.8	11

#	ARTICLE	IF	CITATIONS
1368	Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 767-777.	1.1	8
1369	A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatelliteâ€stable metastatic colorectal cancer. <i>Cancer Medicine</i> , 2021, 10, 1183-1190.	1.3	19
1370	Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs (Review). <i>Oncology Letters</i> , 2021, 21, 315.	0.8	8
1371	Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 974-977.	0.5	1
1372	Targeting KRAS in Colorectal Cancer. <i>Current Oncology Reports</i> , 2021, 23, 28.	1.8	24
1373	Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2067.	1.8	14
1374	Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 465-e917.	1.9	13
1375	Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 704-715.	1.9	10
1376	Targeted drug delivery strategies for precision medicines. <i>Nature Reviews Materials</i> , 2021, 6, 351-370.	23.3	388
1377	Diagnosis and Treatment of Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 669.	3.8	941
1378	Advances in Immuno-oncology for the Treatment of Colorectal and Anal Cancers. <i>Digestive Disease Interventions</i> , 2021, 05, 070-076.	0.3	0
1379	Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor. <i>Kidney Medicine</i> , 2021, 3, 294-298.	1.0	3
1380	Liver Transplantation for Colorectal Liver Metastases: Current Management and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3093.	1.8	7
1382	The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials. <i>Cancers</i> , 2021, 13, 1092.	1.7	40
1383	Abundance of Microvascular Endothelial Cells Is Associated with Response to Chemotherapy and Prognosis in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1477.	1.7	19
1384	Locoregional Therapies for Colorectal Cancer Liver Metastases: Options Beyond Resection. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 133-146.	1.8	5
1385	Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. <i>Cancers</i> , 2021, 13, 1031.	1.7	21
1386	Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Scientific Reports</i> , 2021, 11, 7118.	1.6	5

#	ARTICLE	IF	CITATIONS
1387	Dynamic roles of inflammasomes in inflammatory tumor microenvironment. <i>Npj Precision Oncology</i> , 2021, 5, 18.	2.3	31
1388	Optimizing Regorafenib Dosing and Patient Management in Colorectal Cancer in Latin America: Perspectives from Argentina. <i>Oncologist</i> , 2021, 26, e992-e995.	1.9	0
1389	Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome. <i>Cancers</i> , 2021, 13, 1130.	1.7	15
1390	Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). <i>Frontiers in Oncology</i> , 2021, 11, 576036.	1.3	4
1391	Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis. <i>Cancers</i> , 2021, 13, 1371.	1.7	10
1392	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021, 26, 610-618.	1.9	5
1393	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021, 9, 318.	1.4	7
1394	Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation. <i>Pharmaceutics</i> , 2021, 13, 386.	2.0	6
1395	Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6889-6909.	2.0	6
1396	Emerging strategies for treating metastasis. <i>Nature Cancer</i> , 2021, 2, 258-270.	5.7	71
1397	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	2.3	758
1398	A meta-analysis of Watson for Oncology in clinical application. <i>Scientific Reports</i> , 2021, 11, 5792.	1.6	58
1399	Bevacizumab Combined with Sunitinib and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. <i>Oncologist</i> , 2021, 26, e1320-e1326.	1.9	3
1400	Subgroup analysis by prior anti-VEGF for anti-EGFR target therapy in FRESKO, a randomized, double-blind, Phase III trial. <i>Future Oncology</i> , 2021, 17, 1339-1350.	1.1	5
1401	Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1257-1263.	1.0	13
1402	Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting. <i>International Journal of Cancer</i> , 2021, 149, 409-419.	2.3	6
1403	Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612774.	1.8	21
1404	5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. <i>Frontiers in Oncology</i> , 2021, 11, 658636.	1.3	57

#	ARTICLE	IF	CITATIONS
1405	Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	3
1406	S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial. <i>ESMO Open</i> , 2021, 6, 100077.	2.0	4
1407	Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment. <i>Anticancer Research</i> , 2021, 41, 2203-2207.	0.5	2
1408	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1941.	1.7	21
1409	Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer. <i>BMC Gastroenterology</i> , 2021, 21, 184.	0.8	0
1410	Nephrotoxicity of Anti-Angiogenic Therapies. <i>Diagnostics</i> , 2021, 11, 640.	1.3	16
1411	Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes. <i>Cancer Discovery</i> , 2021, 11, 1644-1660.	7.7	11
1412	Analysis of adverse events attribution and reporting in cancer clinical trials: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103296.	2.0	5
1413	Precision oncology in metastatic colorectal cancer – from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 506-525.	12.5	113
1414	A phase I dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2021, 39, 1335-1347.	1.2	1
1415	Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. <i>Investigational New Drugs</i> , 2021, 39, 1422-1431.	1.2	5
1416	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESKO trial. <i>Future Oncology</i> , 2021, 17, 1923-1931.	1.1	2
1417	The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. <i>Cancers</i> , 2021, 13, 2296.	1.7	47
1418	Targeting the VEGF Pathway in Osteosarcoma. <i>Cells</i> , 2021, 10, 1240.	1.8	24
1419	Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience. <i>Anticancer Research</i> , 2021, 41, 2553-2561.	0.5	2
1420	Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 1749-1759.	1.1	0
1421	Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 684309.	1.3	7
1422	Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy – The Randomized NORDIC9-Study. <i>Cancers</i> , 2021, 13, 2604.	1.7	13

#	ARTICLE	IF	CITATIONS
1423	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789.	5.1	234
1424	Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12096.	5.5	20
1425	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	0.8	7
1426	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5246.	1.8	9
1427	Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. <i>Gastroenterology</i> , 2021, 160, 1947-1960.	0.6	42
1428	FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 564.	1.1	3
1429	Comprehensive molecular profiling of pulmonary pleomorphic carcinoma. <i>Npj Precision Oncology</i> , 2021, 5, 57.	2.3	6
1430	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e08253.	3.3	18
1431	Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice. <i>Annals of Translational Medicine</i> , 2021, 9, 1027-1027.	0.7	2
1432	Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 55.	1.3	4
1433	The Emerging Roles of Pericytes in Modulating Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 676342.	1.8	37
1434	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , 2021, 17, 1977-1985.	1.1	24
1435	Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2021, 41, 3091-3097.	0.5	0
1436	Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. <i>Molecular Oncology</i> , 2021, 15, 2401-2411.	2.1	11
1437	Treatment sequencing of metastatic colorectal cancer based on primary tumor location. <i>Seminars in Oncology</i> , 2021, 48, 119-129.	0.8	4
1438	Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies. <i>Drugs and Aging</i> , 2021, 38, 639-654.	1.3	1
1439	Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 688709.	1.3	5
1440	Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study. <i>Academic Radiology</i> , 2021, 28, S210-S217.	1.3	1

#	ARTICLE	IF	CITATIONS
1441	Targeted agents in older patients with gastrointestinal cancers – An overview. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1240-1252.	0.5	0
1442	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. <i>World Journal of Gastroenterology</i> , 2021, 27, 4104-4142.	1.4	15
1443	Lactate Dehydrogenase Is a Useful Marker for Predicting the Efficacy of Bevacizumab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2021, 41, 3535-3542.	0.5	1
1444	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 314-317.	1.0	12
1445	Colorectal Cancer: From Genetic Landscape to Targeted Therapy. <i>Journal of Oncology</i> , 2021, 2021, 1-17.	0.6	28
1446	Current research progress in targeted anti-angiogenesis therapy for osteosarcoma. <i>Cell Proliferation</i> , 2021, 54, e13102.	2.4	39
1447	Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. <i>Clinical Colorectal Cancer</i> , 2021, 20, 326-333.	1.0	2
1448	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3504.	1.7	5
1449	Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. <i>Scientific Reports</i> , 2021, 11, 15370.	1.6	2
1450	Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2021, 41, 3905-3915.	0.5	4
1451	Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	0
1452	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. <i>Cancer Management and Research</i> , 2021, Volume 13, 5523-5533.	0.9	6
1453	Novel Biomarker-Targeted Therapies for Metastatic Colorectal Cancer. <i>Digestive Disease Interventions</i> , 0, , .	0.3	0
1454	Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2993-3002.	1.2	13
1455	The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids. <i>PLoS ONE</i> , 2021, 16, e0253258.	1.1	8
1456	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. <i>Oncologist</i> , 2021, 26, e1786-e1799.	1.9	52
1457	Risk of Thrombocytopenia With Platelet-Derived Growth Factor Receptor Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized, Controlled Trials. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1397-1405.	1.0	2
1459	TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. , 2021, 224, 107823.		10

#	ARTICLE	IF	CITATIONS
1460	Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report. <i>Immunotherapy</i> , 2021, 13, 1317-1323.	1.0	4
1461	Place of regorafenib in treatment of patients with metastatic colorectal cancer: when are all options exhausted? Or in third line?. <i>Medical Alphabet</i> , 2021, , 30-35.	0.0	0
1462	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	3.4	80
1463	Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks. <i>Frontiers in Pharmacology</i> , 2021, 12, 711126.	1.6	0
1464	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3151-3162.	1.1	14
1465	<i>KRAS</i> mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1325-1334.	1.4	4
1466	Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic. <i>Journal of Modern Oncology</i> , 2021, 23, 256-259.	0.1	0
1467	Lentinan as a natural stabilizer with bioactivities for preparation of drug drug nanosuspensions. <i>International Journal of Biological Macromolecules</i> , 2021, 184, 101-108.	3.6	18
1468	RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody. <i>European Journal of Radiology</i> , 2021, 141, 109823.	1.2	4
1469	Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center. <i>Oncologist</i> , 2021, 26, e2161-e2169.	1.9	8
1470	Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 397-406.	1.0	4
1471	Black Disparities in Targeted Therapy Clinical Trials – A Call for Future Reset. <i>Journal of Education and Teaching in Emergency Medicine</i> , 2021, 7, 8-28.	0.0	1
1472	Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. <i>European Journal of Cancer</i> , 2021, 153, 142-152.	1.3	12
1473	Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5979-5992.	3.2	5
1474	Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. <i>ESMO Open</i> , 2021, 6, 100222.	2.0	10
1475	Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 288.	3.5	50
1476	An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. <i>European Journal of Cancer</i> , 2021, 154, 201-208.	1.3	14
1477	Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5363-5373.	0.8	1



#	ARTICLE	IF	CITATIONS
1478	High-throughput screening on cochlear organoids identifies VEGFR-MEK-TGFB1 signaling promoting hair cell reprogramming. <i>Stem Cell Reports</i> , 2021, 16, 2257-2273.	2.3	11
1479	Bevacizumab and an exelkto inhibitor, TP-0903 inhibits TGF- $\beta$ 21-induced epithelial-to-mesenchymal transition of colon cancer cells. <i>Anti-Cancer Drugs</i> , 2022, 33, e453-e461.	0.7	5
1480	Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment. <i>Medicine (United States)</i> , 2021, 100, e27013.	0.4	4
1481	Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 728854.	1.3	5
1482	Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. <i>Clinical Colorectal Cancer</i> , 2021, 20, e173-e184.	1.0	7
1483	Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress. <i>Frontiers in Oncology</i> , 2021, 11, 719623.	1.3	5
1484	Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers. <i>Frontiers in Molecular Medicine</i> , 2021, 1, .	0.6	1
1485	Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	10
1486	Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study. <i>Cancers</i> , 2021, 13, 4731.	1.7	32
1487	Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 653319.	2.2	7
1488	Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. <i>Cancers</i> , 2021, 13, 4444.	1.7	42
1489	A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3309-3319.	1.1	1
1490	Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. <i>Future Oncology</i> , 2021, 17, 3343-3353.	1.1	2
1491	Hand-foot syndrome and risk factors for occurrence in hematopoietic stem cell transplantation recipients. <i>Supportive Care in Cancer</i> , 2021, , 1.	1.0	0
1492	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021, 20, 227-235.	1.0	10
1493	Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. <i>Cell Reports Medicine</i> , 2021, 2, 100383.	3.3	49
1494	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. <i>Cancers</i> , 2021, 13, 4506.	1.7	11
1495	Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 243.	0.4	4

#	ARTICLE	IF	CITATIONS
1496	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study. <i>PLoS ONE</i> , 2021, 16, e0257551.	1.1	0
1497	Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021, , 100793.	1.0	1
1498	Metastatik Kolorektal Kanserde Kurtarma Tedavisi:Regorafenib. Sleyman Demirel niversitesi Tp Fakltesi Dergisi, 0, , .	0.0	0
1499	Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. <i>Cancer Letters</i> , 2021, 521, 119-129.	3.2	16
1500	Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer. <i>Journal of Colloid and Interface Science</i> , 2022, 607, 229-241.	5.0	5
1501	Application and Progress of Targeted Drug Therapy for Colorectal Cancer. <i>World Journal of Cancer Research</i> , 2021, 11, 24-31.	0.1	1
1502	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 317-324.	1.0	4
1503	Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110091.	1.4	4
1504	Nivolumab plus regorafenib in patients with small bowel adenocarcinoma. <i>Medicine (United States)</i> , 2021, 100, e24295.	0.4	3
1505	Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. <i>Methods in Molecular Biology</i> , 2016, 1386, 181-219.	0.4	12
1506	Discovery and Development of RRx-001, a Novel Nitric Oxide and ROS Mediated Epigenetic Modulator. , 2015, , 259-277.		2
1507	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 211-226.		5
1508	Clinical Treatment in Colorectal Cancer: Other Aspects. , 2017, , 145-154.		1
1509	Regorafenib. <i>Recent Results in Cancer Research</i> , 2014, 201, 185-196.	1.8	22
1510	Neue Arzneimittel 2013. , 2014, , 47-145.		2
1511	Onkologika. , 2016, , 583-619.		1
1512	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1341-1356.	1.0	12
1513	Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 428-433.	0.4	7

#	ARTICLE	IF	CITATIONS
1515	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , 2020, 19, 301-310.e1.	1.0	9
1516	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020, 133, 66-73.	1.3	19
1517	Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy. <i>Seminars in Interventional Radiology</i> , 2017, 34, 116-120.	0.3	3
1518	Prolonged clinical response with regorafenib administered as second-line therapy in an elderly patient suffering from peritoneal carcinomatosis of colon cancer. <i>Journal of Chemotherapy</i> , 2021, 33, 187-192.	0.7	1
1519	Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 333-341.	1.9	3
1520	In Reply: Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 905-906.	0.6	1
1521	Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Oncology</i> , 2017, 93, 329-335.	0.9	14
1522	“Right Drug for the Right Patient”: Hurdles and the Path Forward in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e115-e120.	1.8	6
1523	Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2 $\pm$ (HIF-2 $\pm$ ) and 30 kDa HIV Tat-Interacting Protein (TIP30). <i>Medical Science Monitor</i> , 2018, 24, 2225-2234.	0.5	17
1524	Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials. <i>Medical Science Monitor</i> , 2019, 25, 9179-9191.	0.5	16
1525	Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins. <i>F1000Research</i> , 2017, 6, 587.	0.8	35
1526	Bibliometric analysis of randomized controlled trials of colorectal cancer over the last decade. <i>World Journal of Clinical Cases</i> , 2020, 8, 3021-3030.	0.3	4
1527	Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer. <i>The Journal of Oncopathology</i> , 2013, 1, 21-29.	0.1	1
1529	Monitoring Early Response to Anti-Angiogenic Therapy: Diffusion-Weighted Magnetic Resonance Imaging and Volume Measurements in Colon Carcinoma Xenografts. <i>PLoS ONE</i> , 2014, 9, e106970.	1.1	8
1530	Cost-Effectiveness of Aspirin Adjuvant Therapy in Early Stage Colorectal Cancer in Older Patients. <i>PLoS ONE</i> , 2014, 9, e107866.	1.1	3
1531	Correlation of Perfusion MRI and 18F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation. <i>PLoS ONE</i> , 2015, 10, e0115543.	1.1	6
1532	Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. <i>PLoS ONE</i> , 2015, 10, e0121891.	1.1	30
1533	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. <i>PLoS ONE</i> , 2015, 10, e0134731.	1.1	38

#	ARTICLE	IF	CITATIONS
1534	Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models. <i>PLoS ONE</i> , 2015, 10, e0142612.	1.1	40
1535	Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0145004.	1.1	20
1536	The Effects of Irreversible Electroporation on the Colon in a Porcine Model. <i>PLoS ONE</i> , 2016, 11, e0167275.	1.1	9
1537	Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation. <i>PLoS ONE</i> , 2017, 12, e0169323.	1.1	23
1538	Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway. <i>PLoS ONE</i> , 2017, 12, e0177335.	1.1	17
1539	LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1. <i>PLoS ONE</i> , 2020, 15, e0223035.	1.1	19
1540	Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature. <i>Medicine and Pharmacy Reports</i> , 2018, 91, 12-17.	0.2	10
1541	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. <i>Oncologist</i> , 2020, 25, e130-e137.	1.9	19
1542	Is it necessary to add anti-angiogenic therapy to chemotherapy in patients with metastatic colorectal cancer and BRAF mutation? The systematic review and meta-analysis results. <i>Malignant Tumours</i> , 2020, 10, 36-44.	0.1	3
1543	Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59087-59097.	0.8	65
1544	Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 68749-68767.	0.8	36
1545	Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation. <i>Oncotarget</i> , 2016, 7, 73525-73540.	0.8	48
1546	Selenite inhibits glutamine metabolism and induces apoptosis by regulating GLS1 protein degradation via APC/C-CDH1 pathway in colorectal cancer cells. <i>Oncotarget</i> , 2017, 8, 18832-18847.	0.8	25
1547	Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. <i>Oncotarget</i> , 2017, 8, 38193-38213.	0.8	22
1548	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. <i>Oncotarget</i> , 2017, 8, 57882-57888.	0.8	10
1549	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 68305-68316.	0.8	27
1550	RRS1 silencing suppresses colorectal cancer cell proliferation and tumorigenesis by inhibiting G2/M progression and angiogenesis. <i>Oncotarget</i> , 2017, 8, 82968-82980.	0.8	32
1551	Incidence and risk of regorafenib-induced hepatotoxicity. <i>Oncotarget</i> , 2017, 8, 84102-84111.	0.8	9

#	ARTICLE	IF	CITATIONS
1552	Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib. <i>Oncotarget</i> , 2017, 8, 93813-93824.	0.8	5
1553	Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism. <i>Oncotarget</i> , 2017, 8, 103952-103967.	0.8	11
1554	SHP-1 is a target of regorafenib in colorectal cancer. <i>Oncotarget</i> , 2014, 5, 6243-6251.	0.8	50
1555	Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib. <i>Oncotarget</i> , 2017, 8, 110530-110539.	0.8	11
1556	Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. <i>Oncotarget</i> , 2017, 8, 113444-113459.	0.8	19
1557	Copy number profiles of paired primary and metastatic colorectal cancers. <i>Oncotarget</i> , 2018, 9, 3394-3405.	0.8	14
1558	Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. <i>Oncotarget</i> , 2018, 9, 17756-17769.	0.8	34
1559	The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. <i>Oncotarget</i> , 2018, 9, 36220-36237.	0.8	20
1560	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	0.8	11
1561	Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study. <i>Oncotarget</i> , 2019, 10, 3840-3851.	0.8	8
1562	Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 8300-8312.	0.8	30
1563	Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. <i>Oncotarget</i> , 2015, 6, 5041-5058.	0.8	24
1564	The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 6053-6061.	0.8	15
1565	Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. <i>Oncotarget</i> , 2015, 6, 11820-11832.	0.8	67
1566	Identification and characterization of RET fusions in advanced colorectal cancer. <i>Oncotarget</i> , 2015, 6, 28929-28937.	0.8	94
1567	Prokineticin 2 (PROK2) is an important factor for angiogenesis in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 26242-26251.	0.8	31
1568	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. <i>Oncotarget</i> , 2015, 6, 26388-26399.	0.8	9
1569	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. <i>Oncotarget</i> , 2015, 6, 33982-33992.	0.8	46

#	ARTICLE	IF	CITATIONS
1570	Changes in expression levels of <i>ERCC1</i> , <i>DPYD</i> and <i>VEGFA</i> mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. <i>Oncotarget</i> , 2015, 6, 34004-34013.	0.8	13
1571	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015, 6, 39538-39549.	0.8	27
1572	Genomic markers of panitumumab resistance including <i>ERBB2/HER2</i> in a phase II study of <i>KRAS</i> wild-type (wt) metastatic colorectal cancer (mCRC). <i>Oncotarget</i> , 2016, 7, 18953-18964.	0.8	11
1573	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 46678-46691.	0.8	35
1574	Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 55732-55740.	0.8	15
1575	Anaphylaxis and anaesthesia “ can treating a cough kill?. <i>Australian Prescriber</i> , 2014, 37, 74-76.	0.5	1
1576	Translational research and application of basic biology to clinical trial development in GI cancers. <i>Annals of Translational Medicine</i> , 2018, 6, 164-164.	0.7	6
1577	IMblaze 370: lessons learned and future strategies in colorectal cancer treatment. <i>Annals of Translational Medicine</i> , 2019, 7, 602-602.	0.7	3
1578	Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 614-624.	0.6	41
1579	Chemotherapy re-challenge response rate in metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 679-686.	0.6	12
1580	Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 508-515.	0.7	2
1581	&lt;p&gt;Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13023-13032.	1.0	66
1582	Therapeutic Potential of Targeting Transforming Growth Factor-beta in Colorectal Cancer: Rational and Progress. <i>Current Pharmaceutical Design</i> , 2019, 25, 4085-4089.	0.9	13
1583	Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. <i>Current Drug Targets</i> , 2016, 18, 56-71.	1.0	25
1584	Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. <i>Current Drug Targets</i> , 2019, 20, 1180-1202.	1.0	13
1585	Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2016, 16, 175-185.	0.8	8
1586	Cetuximab/Irinotecan-Chemotherapy in <i>KRAS</i> Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature.. <i>Reviews on Recent Clinical Trials</i> , 2013, 8, 101-109.	0.4	9
1587	A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer. , 2017, 37, 5851-5855.		3

#	ARTICLE	IF	CITATIONS
1588	A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 5925-5934.	0.5	15
1589	Prognostic Significance of the C-Reactive Protein-to-Albumin Ratio in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Thymidine Phosphorylase Inhibitor as Later-line Chemotherapy. <i>Anticancer Research</i> , 2019, 39, 1051-1057.	0.5	18
1590	A case of multiple hepatocellular carcinoma tumors with thoracic vertebra and adrenal gland metastases successfully treated with prolonged administration of reduced-dose regorafenib for more than 12 months. <i>Acta Hepatologica Japonica</i> , 2020, 61, 426-433.	0.0	1
1591	Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis. <i>Ecancermedalscience</i> , 2020, 14, 1069.	0.6	15
1592	Long-term treatment response on therapy trifluridin/tipiracil (Lonsurf®) in patient with metastatic colorectal cancer. <i>Onkologie (Czech Republic)</i> , 2020, 14, 62-66.	0.0	1
1593	Angiogenic inhibitors for older patients with advanced colorectal cancer: Does the age hold the stage?. <i>World Journal of Gastroenterology</i> , 2013, 19, 2131.	1.4	5
1594	Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives. <i>World Journal of Gastroenterology</i> , 2013, 19, 7955.	1.4	30
1595	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 8474.	1.4	9
1596	Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 3858.	1.4	44
1597	Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 6102.	1.4	45
1598	Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. <i>World Journal of Gastroenterology</i> , 2014, 20, 7602.	1.4	53
1599	Personalizing medicine for metastatic colorectal cancer: Current developments. <i>World Journal of Gastroenterology</i> , 2014, 20, 10425.	1.4	12
1600	Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone?. <i>World Journal of Gastroenterology</i> , 2014, 20, 12391.	1.4	48
1601	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. <i>World Journal of Gastroenterology</i> , 2015, 21, 11793.	1.4	29
1602	Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. <i>World Journal of Gastroenterology</i> , 2016, 22, 3127.	1.4	34
1603	Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. <i>World Journal of Gastroenterology</i> , 2016, 22, 4638.	1.4	13
1604	Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 490.	1.4	38
1605	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. <i>World Journal of Gastroenterology</i> , 2016, 22, 5668.	1.4	14

#	ARTICLE	IF	CITATIONS
1606	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	7
1607	Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 14, 30.	0.4	1
1608	Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report. <i>Oncology Letters</i> , 2019, 18, 6469-6474.	0.8	3
1609	Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1188-1196.	0.7	3
1610	Analysis of Sensitivity and Cell Death Pathways Mediated by Anti-cancer Drugs Using Three-dimensional Culture System. <i>International Journal of Cancer Research</i> , 2017, 14, 1-12.	0.2	5
1611	Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 231-8.	0.6	18
1612	Understanding and targeting resistance to anti-angiogenic therapies. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 253-63.	0.6	66
1613	Regorafenib-induced transverse myelopathy after stereotactic body radiation therapy. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, E128-31.	0.6	8
1614	Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 134-42.	0.6	81
1615	Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 594-604.	0.6	14
1616	Chemotherapy for advanced cancers. <i>Annals of Palliative Medicine</i> , 2014, 3, 203-28.	0.5	11
1617	Meta-analysis of molecular targeted agents in the treatment of elderly patients with metastatic colorectal cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, S79-S84.	0.3	8
1618	Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2016, 3, 58-65.	0.7	12
1619	A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or <i>POLE</i>-Mutated Metastatic or Unresectable Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1135-1144.	1.3	43
1620	KDR gene as a Predictive Biomarker of Response to Regorafenib in Patients with Metastatic Colorectal Cancer (mCRC). <i>Journal of Pharmacogenomics &amp; Pharmacoproteomics</i> , 2017, 08, .	0.2	1
1621	Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival. <i>Journal of Cancer Therapy</i> , 2014, 05, 1270-1288.	0.1	1
1622	New active drugs for the treatment of advanced colorectal cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2015, 7, 356.	0.8	8
1623	Endothelial cells in colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 946-956.	0.8	29



#	ARTICLE	IF	CITATIONS
1624	Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1364-1371.	0.8	2
1625	Anti-angiogenic agents in metastatic colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 71.	0.8	22
1626	Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 83.	0.8	23
1627	Novel therapeutic agents in the treatment of metastatic colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 99.	0.8	22
1628	Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA approval descriptive study with a geriatric oncology focus. <i>Turkish Journal of Gastroenterology</i> , 2020, 31, 695-705.	0.4	1
1629	Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2019, 10, 75-85.	0.9	7
1630	Colorectal liver metastases: Current management and future perspectives. <i>World Journal of Clinical Oncology</i> , 2020, 11, 761-808.	0.9	98
1631	Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review. <i>World Journal of Clinical Oncology</i> , 2020, 11, 959-967.	0.9	6
1632	Nephrotoxicity in cancer treatment: An overview. <i>World Journal of Clinical Oncology</i> , 2020, 11, 190-204.	0.9	64
1633	Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST. <i>Journal of the Advanced Practitioner in Oncology</i> , 2013, 4, 118-22.	0.2	2
1634	Regorafenib-Related Myocardial Injury during Atrial Fibrillation. <i>Acta Cardiologica Sinica</i> , 2016, 32, 243-6.	0.1	6
1635	Efficacy and Toxicity of Anti-VEGF Agents in Patients with Castration-Resistant Prostate Cancer: a Meta-analysis of Prospective Clinical Studies. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 8177-8182.	0.5	5
1636	Efficacy and Safety of Raltitrexed Combinations with Uracil-Tegafur or Mitomycin C as Salvage Treatment in Advanced Colorectal Cancer Patients: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO). <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 1845-1849.	0.5	5
1637	TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study. <i>Drugs in Context</i> , 2020, 9, 1-8.	1.0	6
1638	Current Treatment Strategies for Elderly Patients with Metastatic Colon Cancer. <i>Cureus</i> , 2019, 11, e4713.	0.2	6
1639	Targeted Therapy. <i>UNIPA Springer Series</i> , 2021, , 181-206.	0.1	0
1641	18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12). <i>Oncology and Therapy</i> , 2021, 9, 635-645.	1.0	2
1642	Radioembolization in the Setting of Systemic Therapies. <i>Seminars in Interventional Radiology</i> , 2021, 38, 472-478.	0.3	1

#	ARTICLE	IF	CITATIONS
1643	Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases. <i>American Journal of Surgery</i> , 2022, 223, 1151-1156.	0.9	4
1644	Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1443-1451.	2.0	13
1645	ASCO 2021 "an update on metastatic colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 319-322.	0.3	1
1646	Diverse landscape of dermatologic toxicities from small molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	0.7	5
1647	Genomic landscape of treatment refractory metastatic colorectal cancer. <i>Acta Oncologica</i> , 2021, 60, 1621-1628.	0.8	2
1648	Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment. <i>Cancers</i> , 2021, 13, 5080.	1.7	8
1649	Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 131.	1.0	0
1650	Radioembolization of Secondary Hepatic Malignancies. <i>Seminars in Interventional Radiology</i> , 2021, 38, 445-452.	0.3	7
1651	Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer. <i>Farmakoekonomika</i> , 2021, 14, 291-298.	0.4	0
1652	Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754881.	1.3	15
1653	Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting. <i>Dose-Response</i> , 2021, 19, 155932582110476.	0.7	1
1654	Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. <i>Immunotherapy</i> , 2021, 13, 1355-1367.	1.0	2
1655	Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. <i>Journal of Controlled Release</i> , 2021, 340, 1-34.	4.8	11
1657	Efficacy and optimal treatment sequence of Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2013, 54, 233-248.	0.0	2
1658	A successful rechallenge with cetuximab for a case with metastatic rectal cancer. <i>Okayama Igakkai Zasshi</i> , 2013, 125, 51-55.	0.0	0
1659	Molecular targeted therapies and gastroenterological neoplasia. <i>Okayama Igakkai Zasshi</i> , 2013, 125, 145-152.	0.0	0
1660	"Right Drug for the Right Patient": Hurdles and the Path Forward in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e115-e120.	1.8	5
1661	MET Inhibitors. , 2013, , 209-234.		1

#	ARTICLE	IF	CITATIONS
1662	The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients. , 2014, , 135-142.		0
1663	RAS Genes and Cancer. , 2014, , 157-171.		0
1664	Anti-angiogenic Therapies in Colorectal Cancer. , 2014, , 383-396.		0
1665	Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. World Journal of Gastroenterology, 2014, 20, 10288.	1.4	3
1667	Future Perspective of Chemotherapy for Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2014, 67, 906-918.	0.1	0
1668	Pitfalls in Clinical Research. The Case of the New Antineoplastic Agents. Global & Regional Health Technology Assessment, 2014, 1, GRHTA.5000183.	0.2	1
1669	Metastatic Rectal Cancer. , 2015, , 287-310.		0
1670	Biomarkers in Metastatic Colorectal Cancer. Biomarkers in Disease, 2015, , 601-629.	0.0	1
1671	Targeted Therapies For Intestinal Tumorigenesis. , 2015, , 391-440.		0
1672	Risk Factors of Hand-foot Skin Reaction Caused by Regorafenib in Patients with Unresectable Advanced or Recurrent Colorectal Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq1 1 0.784314 rgBT /Overlook	0.0	0
1673	Study on the Feasibility and Safety of Chemotherapy with S-1 and Irinotecan in Elderly Patients with Unresectable Advanced/recurrent Colorectal Cancer. Iryo Yakugaku (Japanese Journal of) Tj ETQq0 0 0 rgBT /Overlook10 Tf 50 337 Td (F	0.0	0
1674	Targeted Therapies for Colorectal Cancer. Current Clinical Pathology, 2015, , 147-162.	0.0	0
1676	æ-°è   æŠ-ãCEã,“ã%regorafenibi¼ã,1ãfãfãf¼ã,-i¼%ã@ãSè...ãCEã,“æ²»ç™,ã«ãŠããã,«ã½ç½ç®ã¥ã. Skin Cancer2015, 29, 123-125.		0
1677	ã,1ãfãfãf¼ã,-ã«ãŠããã,«æ%«è¶³ç-‡ã€™ç³¼ã@ãfžãfã,ãf;ãf³ãf^ . Skin Cancer, 2015, 29, 126-127.	0.1	0
1679	Onkologika. , 2015, , 833-876.		0
1680	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
1681	Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150025.	0.2	12
1682	Multimodality Management of Oligometastatic Colorectal Cancer. , 2015, , 311-350.		0

#	ARTICLE	IF	CITATIONS
1683	Regorafenib-Induced Hyperammonemic Encephalopathy in Metastatic Colon Cancer. Journal of Cancer Prevention & Current Research, 2015, 3, .	0.1	1
1685	Episensitization. , 2016, , 407-436.		1
1687	Regorafenib- associated panniculitis. Dermatology Online Journal, 2016, 22, .	0.2	5
1688	METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY. Farmakoekonomika, 2016, 9, 38-44.	0.4	1
1689	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
1690	VEGF Ligands. , 2016, , 1-20.		0
1691	Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. Cancer Treatment and Research, 2016, 168, 393-479.	0.2	0
1692	Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 179-188.	0.1	0
1693	Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 27-107.	0.1	0
1695	Colorectal and Anal Tumors. Pediatric Oncology, 2017, , 319-333.	0.5	0
1696	Principles of Cancer Targeted Therapy in Older Adults. , 2017, , 1-15.		0
1697	Basics of Chemotherapy. , 2017, , 1-10.		0
1698	Utility of Primary Tumor Resection in Asymptomatic, Unresectable Metastatic Colon and Rectal Cancer. Difficult Decisions in Surgery: an Evidence-based Approach, 2017, , 139-152.	0.0	1
1699	Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study. AIMS Medical Science, 2017, 4, 456-464.	0.2	1
1700	Systemic chemotherapy for hepatic colorectal cancer. , 2017, , 1488-1501.e5.		0
1702	Unresectable colorectal cancer liver metastases treated with radioembolization: Updated survival analysis of the MORE study.. Journal of Clinical Oncology, 2017, 35, 666-666.	0.8	0
1704	Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget, 2017, 8, 93179-93185.	0.8	2
1705	Rechallenge chemotherapy as a third line treatment option for metastatic colorectal carcinoma. OrtadoÄŸu TÄ±p Dergisi, 2017, 9, 163-169.	0.1	0

#	ARTICLE	IF	CITATIONS
1706	Salvage Line Chemotherapies in Metastatic Colorectal Cancer Patients. Nihon Daicho Komonbyo Gakkai Zasshi, 2018, 71, 387-392.	0.1	1
1707	Kolorektales Karzinom. , 2018, , 273-341.		0
1708	The application of the modern target medications for the treatment of metastatic colorectal cancer. Russian Journal of Evidence-Based Gastroenterology, 2018, 7, 21.	0.3	1
1709	Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. , 2018, , 245-260.		0
1710	Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. , 2018, , 191-224.		0
1711	Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment. Cureus, 2018, 10, e2798.	0.2	1
1712	Traitement du cancer colorectal mÃ©tastatique : ciblage molÃ©culaire. Colon and Rectum, 2018, 12, 178-183.	0.0	0
1713	Molecular Target Therapy for Digestive Malignancy. Nihon Ika Daigaku Igakkai Zasshi, 2018, 14, 169-172.	0.0	0
1714	Conventional and targeted therapy in metastatic colorectal cancer. Journal of Cancer Prevention & Current Research, 2018, 9, .	0.1	1
1715	Outcomes of Refractory Metastatic Colorectal Cancer Patients Treated with Regorafenib and Trifluridine / Tipiracil as Late Line Treatment. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese) Tj ETQq1 1 0.784314 rgBT dOverlock	0.1	1
1717	Recent advances in the systemic treatment of gastrointestinal malignancy. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 336.	0.1	0
1718	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. , 2019, , 1-16.		0
1719	Observation of the high efficiency of therapy for metastatic colorectal cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 366.	0.0	0
1720	Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study. South Asian Journal of Cancer, 2019, 08, 22-26.	0.2	2
1721	Study Protocol of Regorafenib Escalation for Colorectal Cancer (RECC): A Phase II Multicenter Clinical Trial of the Efficacy and Safety of Regorafenib Dose Escalation Therapy as the Third or Fourth Line Therapy for Unresectable/Recurrent Colorectal Cancer. Juntendo Medical Journal, 2019, 65, 85-91.	0.1	1
1722	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. , 2019, , 407-444.		0
1723	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2019, , 379-394.		0
1724	Metastatic Colorectal Cancer. , 2019, , 135-160.		0

#	ARTICLE	IF	CITATIONS
1725	Association between Germline Mutations in the RET Proto-Oncogene and Colorectal Cancer and Polypos. <i>Advanced Research in Gastroenterology &amp; Hepatology</i> , 2019, 12, .	0.1	1
1726	æŕŕâĈE—â™™ăĈEă,“. <i>Journal of Otolaryngology of Japan</i> , 2019, 122, 717-723.	0.1	0
1727	The use of regorafenib in colorectal cancer. <i>Journal of Modern Oncology</i> , 2019, 21, 33-36.	0.1	0
1729	An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era. <i>Journal of Liver Cancer</i> , 2019, 19, 117-127.	0.3	0
1730	Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims. <i>Current Cancer Therapy Reviews</i> , 2019, 15, 184-191.	0.2	0
1731	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
1732	Treatment and prevention of hand-foot skin reaction â€” dermatological adverse effect of regorafenib (literature review). <i>Medical Alphabet</i> , 2019, 3, 57-61.	0.0	0
1733	Sequencing of Systemic Chemotherapy for Unresectable CRLM. , 2020, , 297-312.		0
1734	Prognosis and Management of Recurrent Metastatic Colorectal Cancer. , 2020, , 571-587.		0
1735	Systemic Treatment for Metastatic or Recurrent Disease. , 2020, , 275-287.		0
1736	Pump-Based Hepatic Arterial Infusional Therapy. , 2020, , 257-264.		1
1737	Liver Resection and HIPEC. , 2020, , 189-197.		0
1738	Revisiting anti-angiogenic therapy for recurrent glioblastoma. <i>Translational Cancer Research</i> , 2019, 8, S569-S572.	0.4	2
1740	Role of Hepatic Artery Infusion Pump Chemotherapy for Unresectable Colorectal Cancer Liver Metastases. , 2020, , 313-327.		1
1741	Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 301-310.	0.8	9
1742	THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS. <i>Farmacia</i> , 2020, 68, 572-578.	0.1	2
1743	Current perspective on the treatment of advanced/metastatic colorectal cancer. <i>Onkologie (Czech) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	0.0	0
1744	Intervention by Pharmacist in Outpatient Service for Lenvatinib Therapy for Hepatocellular Carcinoma at Our Hospital and Its Usefulness. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq1 1 0 0 784314rgBT /Over</i>		

#	ARTICLE	IF	CITATIONS
1745	A REVIEW OF MODERN IMMUNOTHERAPY IN GASTROINTESTINAL MALIGNANT TUMORS. EurasianUnionofScientists, 2020, 6, 9-21.	0.0	0
1747	Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. Cancers, 2021, 13, 5472.	1.7	0
1748	Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09. Targeted Oncology, 2021, 16, 753-760.	1.7	7
1749	Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. Topics in Medicinal Chemistry, 2020, , 125-153.	0.4	0
1750	A phase 1b expansion study of TASâ€œ102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer, 2021, 127, 1417-1424.	2.0	5
1751	Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Current Drug Metabolism, 2020, 21, 866-884.	0.7	8
1752	A roadmap for medical treatment of metastatic CRC. , 2022, , 365-379.		0
1753	Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. Cancer Letters, 2022, 524, 131-143.	3.2	13
1754	Therapeutic Vaccines for Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 113-158.	0.2	1
1755	Principles of Cancer Targeted Therapy in Older Adults. , 2020, , 881-894.		0
1756	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	2.0	4
1758	SystemÃ±c Chemotherapy in Colorectal Cancer. , 2021, , 693-705.		0
1759	A novel prognostic risk score model based on immune-related genes in patients with stage IV colorectal cancer. Bioscience Reports, 2020, 40, .	1.1	9
1760	Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 905-906.	0.6	0
1761	Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer. , 2021, , 187-202.		0
1762	Late COVID-19 metastatic colorectal cancer therapy: to start or to delay?. Medical Alphabet, 2020, , 5-11.	0.0	0
1763	Combining Immunotherapy with Multikinase Inhibitors: A Cautious New Promise. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 901-905.	0.1	0
1764	Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. Annals of Translational Medicine, 2016, 4, 74.	0.7	6

#	ARTICLE	IF	CITATIONS
1765	The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 264-84.	0.6	22
1766	Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, S11-20.	0.6	7
1767	Targeted therapies in colorectal cancer: surgical considerations. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 328-36.	0.6	17
1768	A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 319-27.	0.6	18
1769	Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 299-307.	0.6	6
1770	Status of targeted therapies in the adjuvant treatment of colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 245-52.	0.6	14
1771	Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 99-103.	0.6	4
1772	Which strategy after first-line therapy in advanced colorectal cancer?. <i>World Journal of Gastroenterology</i> , 2014, 20, 8921-7.	1.4	3
1773	Saudi Oncology Society clinical management guideline series. Colorectal cancer 2014. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2014, 35, 1538-44.	0.5	5
1774	Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 21159-65.	1.3	4
1775	Novel Therapies in Development for Metastatic Colorectal Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, S2-7.	0.8	2
1776	The Role of Regorafenib in Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2017, 13, 122-124.	0.2	8
1777	Colorectal Carcinoma and Emerging Targeted Therapies. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2015, 32, 27S-31S.	0.6	0
1779	Impact of BMI1 expression on the apoptotic effect of paclitaxel in colorectal cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 2544-2553.	1.4	3
1780	Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series. <i>Archives of Medical Case Reports</i> , 2020, 2, 23-29.	1.0	2
1781	Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. <i>American Journal of Cancer Research</i> , 2020, 10, 2946-2954.	1.4	7
1782	Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2021, 14, 12.	0.4	1
1783	Personalized medicine in colorectal cancer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2020, 13, S18-S28.	0.6	1



#	ARTICLE	IF	CITATIONS
1784	Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 428-433.	0.7	0
1785	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	1.7	6
1786	Targeting Tie2 in the Tumor Microenvironment: From Angiogenesis to Dissemination. <i>Cancers</i> , 2021, 13, 5730.	1.7	36
1787	A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 690515.	1.3	3
1788	Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases. <i>Transplant International</i> , 2021, 34, 2205-2213.	0.8	13
1789	The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting. <i>Anticancer Research</i> , 2021, 41, 6211-6216.	0.5	2
1790	Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 754858.	1.6	2
1791	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1899-1903.	15.2	110
1792	A Promising Role of TGF- $\beta$ 2 Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1241.	0.8	3
1793	Dermatomyositis Identified During Palliative Care Management for Chemotherapy-Associated Pain: A Case Report. <i>Journal of Palliative Care</i> , 2022, 37, 83-86.	0.4	2
1794	Regorafenib in metastatic colorectal cancer: more data for clinical decisions. <i>Journal of Modern Oncology</i> , 2021, 23, 436-441.	0.1	0
1795	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 792691.	2.2	39
1796	Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. <i>International Immunopharmacology</i> , 2021, 101, 108337.	1.7	3
1797	Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. <i>Clinical Epigenetics</i> , 2022, 14, 3.	1.8	26
1798	Strategies for the treatment of colorectal cancer caused by gut microbiota. <i>Life Sciences</i> , 2022, 290, 120202.	2.0	6
1801	Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2020, 14, 12.	0.4	7
1802	Yttrium-90 Internal Radiation Therapy as Part of the Multimodality Treatment of Metastatic Colorectal Carcinoma. <i>Onco</i> , 2021, 1, 207-218.	0.2	1
1803	Emerging Therapeutic Agents for Colorectal Cancer. <i>Molecules</i> , 2021, 26, 7463.	1.7	14

#	ARTICLE	IF	CITATIONS
1804	Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 802942.	1.6	6
1805	Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. <i>Clinical Colorectal Cancer</i> , 2022, 21, 141-148.	1.0	10
1806	Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1667.	1.8	2
1807	Early detection of treatment futility in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2022, 13, 61-72.	0.8	7
1809	Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective. <i>Future Oncology</i> , 2022, 18, 1313-1320.	1.1	2
1811	Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review. <i>Oncologist</i> , 2022, 27, 210-219.	1.9	7
1812	Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 589-597.	1.0	6
1813	Cost-effectiveness of liver transplantation versus last-resort systemic therapy for colorectal liver metastases. <i>British Journal of Surgery</i> , 2022, 109, 483-485.	0.1	2
1814	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 115-124.	5.1	147
1815	A comprehensive framework for early-onset colorectal cancer research. <i>Lancet Oncology</i> , The, 2022, 23, e116-e128.	5.1	49
1816	Precision medicine for metastatic colorectal cancer in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110727.	1.4	23
1817	Antiangiogenic drugs: Chemosensitizers for combination cancer therapy. , 2022, , 29-66.		1
1818	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. <i>Healthcare (Switzerland)</i> , 2022, 10, 218.	1.0	1
1819	Small-size (40µm) Beads Loaded with Irinotecan in the Treatment of Patients with Colorectal Liver Metastases. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 770-779.	0.9	6
1820	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 406.	1.7	11
1821	Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 276-287.	0.4	10
1822	Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 772225.	1.3	5
1823	Predictive economic biomarkers of drug response: Colorectal cancer as a model. , 2022, , 199-240.		2

#	ARTICLE	IF	CITATIONS
1824	Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. , 2022, 10, e003831.		18
1825	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade. <i>Life</i> , 2022, 12, 229.	1.1	15
1827	Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2022, 29, 3387-3389.	0.7	1
1828	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	5.7	112
1829	Treatment of metastatic colorectal cancer in the year 2020. <i>Onkologie (Czech Republic)</i> , 2021, 14, 258-261.	0.0	0
1830	The sequence of antiVEGF(R) preparations in the treatment of metastatic colorectal carcinoma in 2020. <i>Onkologie (Czech Republic)</i> , 2021, 14, 263-267.	0.0	0
1831	Immunotherapy in the Treatment of Advanced Colorectal Cancer. , 2022, , 113-137.		0
1833	Tumor lysates cancer vaccine. , 2022, , 21-49.		0
1834	Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 663-672.	0.9	3
1835	The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. <i>Cancer Medicine</i> , 2022, , .	1.3	2
1836	Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". <i>Clinical Colorectal Cancer</i> , 2022, 21, 132-140.	1.0	5
1837	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. <i>Cancers</i> , 2022, 14, 1197.	1.7	9
1838	Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes. <i>Frontiers in Radiology</i> , 2022, 1, .	1.2	3
1839	Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study. <i>Frontiers in Oncology</i> , 2022, 12, 813009.	1.3	2
1840	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	2.8	48
1841	Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2022, 33, 389-393.	0.7	5
1842	On the origin of metastases: Induction of pro-metastatic states after impending cell death via ER stress, reprogramming, and a cytokine storm. <i>Cell Reports</i> , 2022, 38, 110490.	2.9	15
1843	Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer. <i>Journal of the Formosan Medical Association</i> , 2022, , .	0.8	3

#	ARTICLE	IF	CITATIONS
1844	Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. Expert Opinion on Investigational Drugs, 2022, 31, 437-441.	1.9	5
1845	Formulation and Characterization of Doxycycline-Loaded Polymeric Nanoparticles for Testing Antitumor/Antiangiogenic Action in Experimental Colon Cancer in Mice. Nanomaterials, 2022, 12, 857.	1.9	9
1846	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O <sup>6</sup> -Methylguanine-“DNA Methyltransferase”-Silenced Metastatic Colorectal Cancer: The MAYA Trial. Journal of Clinical Oncology, 2022, 40, 1562-1573.	0.8	52
1847	Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report. Clinical Case Reports (discontinued), 2022, 10, e05544.	0.2	1
1848	A concise review on tyrosine kinase targeted cancer therapy. Current Drug Therapy, 2022, 17, .	0.2	1
1849	Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. International Journal of Molecular Sciences, 2022, 23, 2815.	1.8	15
1850	A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial. Frontiers in Oncology, 2022, 12, 835582.	1.3	6
1851	The Efficacy and Tolerability of Xeliri-Aflibercept Combination in A Metastatic Colorectal Cancer Patient After 5-Fu- Induced Symptomatic Bradycardia: A Case Report and A Brief Review of Literature. Osmangaz“ Journal of Medicine, 0, , .	0.1	0
1852	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. British Journal of Cancer, 2022, 127, 394-407.	2.9	41
1853	Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. International Journal of Cancer, 2022, 150, 2038-2045.	2.3	19
1854	A Risk Scoring System Utilizing Machine Learning Methods for Hepatotoxicity Prediction One Year After the Initiation of Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2022, 12, 790343.	1.3	1
1855	Cancer Therapies and Vascular Toxicities. Current Treatment Options in Oncology, 2022, 23, 333-347.	1.3	6
1856	Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study. Frontiers in Oncology, 2022, 12, 838870.	1.3	4
1857	Molecular Network of Colorectal Cancer and Current Therapeutic Options. Frontiers in Oncology, 2022, 12, 852927.	1.3	20
1858	The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-9.	0.5	0
1859	Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. European Journal of Cancer, 2022, 165, 116-124.	1.3	6
1860	Current Updates on HER2-“Directed Therapies in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2022, 18, 27.	1.0	0
1861	Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 173, 103657.	2.0	6

#	ARTICLE	IF	CITATIONS
1862	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103663.	2.0	27
1863	Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. <i>CORRECTness and CONCUREncy. Meditsinskiy Sovet</i> , 2021, , 47-52.	0.1	0
1864	Inoperable <i>deÂnov</i> metastatic colorectal cancer with primary tumour <i>inÂsitu</i>: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre). <i>Molecular and Clinical Oncology</i> , 2021, 16, 40.	0.4	0
1865	Species differences in oxidative metabolism of regorafenib. <i>Xenobiotica</i> , 2021, 51, 1400-1407.	0.5	2
1866	Patientsâ€™ Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life. <i>Cancers</i> , 2022, 14, 179.	1.7	5
1867	The value of anticancer drugs â€” a regulatory view. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 207-215.	12.5	14
1868	Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2136378.	2.8	5
1869	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	3.2	11
1870	Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 716-e689.	1.9	5
1871	Development of Tissue-Agnostic Treatments for Patients with Cancer. <i>Annual Review of Cancer Biology</i> , 2022, 6, 147-165.	2.3	8
1872	Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1164-1172.	1.0	5
1873	Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 428.	1.1	4
1874	Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer â€” The PICCASSO phase I trial. <i>European Journal of Cancer</i> , 2022, 167, 112-122.	1.3	35
1885	Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial. <i>BMJ Open</i> , 2022, 12, e049992.	0.8	3
1891	Case Report: Bilateral Pneumothoraces due to Targeted Tumor Therapy with Regorafenib in a Young Woman with Metastatic Colorectal Cancer. <i>Case Reports in Clinical Medicine</i> , 2022, 11, 139-145.	0.1	0
1892	Does Preoperative Waiting Time Affect the Short-Term Outcomes and Prognosis of Colorectal Cancer Patients? A Retrospective Study from the West of China. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-8.	0.8	7
1893	The Evolving Treatment Landscape in <i>BRAF-V600E</i>â€”Mutated Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 254-263.	1.8	13
1894	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	157.7	167

#	ARTICLE	IF	CITATIONS
1895	Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 722-731.	0.6	2
1896	Regorafenib Induces the Apoptosis of Gastrointestinal Cancer-Associated Fibroblasts by Inhibiting AKT Phosphorylation. <i>Stem Cells and Development</i> , 2022, 31, 383-394.	1.1	4
1897	Thyroid Dysfunction from Treatments for Solid Organ Cancers. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 265-286.	1.2	3
1898	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	7.7	48
1899	Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. <i>European Journal of Cancer</i> , 2022, 168, 99-107.	1.3	3
1900	A phase I/IIb study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. <i>European Journal of Cancer</i> , 2022, 169, 93-102.	1.3	30
1902	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 219-232.	1.8	21
1903	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
1904	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72.	1.3	3
1905	Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 852583.	1.3	6
1906	The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts. <i>American Journal of Cancer Research</i> , 2022, 12, 1912-1918.	1.4	0
1907	Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210982.	1.4	0
1908	Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib's Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion. <i>Cancers</i> , 2022, 14, 2492.	1.7	8
1909	Hydrogen Sulfide Biology and Its Role in Cancer. <i>Molecules</i> , 2022, 27, 3389.	1.7	47
1911	Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study). <i>International Journal of Clinical Oncology</i> , 2022, 27, 1300-1308.	1.0	2
1912	An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1913	Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. <i>PLoS ONE</i> , 2022, 17, e0269115.	1.1	2
1914	Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?. <i>Drugs and Therapy Perspectives</i> , 0, , .	0.3	0

#	ARTICLE	IF	CITATIONS
1915	Armamentarium in drug delivery for colorectal cancer. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2022, , .	1.2	2
1916	Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1917	Targeted Cancer Therapy: Tyrosine Kinase Inhibitors. <i>Arsiv Kaynak Tarama Dergisi</i> , 2022, 31, 78-81.	0.1	0
1918	Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity. <i>Neurosurgical Review</i> , 2022, 45, 3201-3208.	1.2	6
1919	Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC). <i>British Journal of Cancer</i> , 2022, 127, 1153-1161.	2.9	7
1920	Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial). <i>Future Oncology</i> , 2022, 18, 2495-2503.	1.1	1
1921	Encorafenib plus cetuximab for the treatment of <i>BRAF-V600E</i> -mutated metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211106.	1.4	4
1922	A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211091.	1.4	3
1923	Survival and Toxicities after <sup>90</sup> Y Transarterial Radioembolization of Metastatic Colorectal Cancer in the RESIN Registry. <i>Radiology</i> , 2022, 305, 228-236.	3.6	17
1924	Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1266-1277.	0.6	3
1925	Immunotherapy for Colorectal Cancer in the Era of Precision Medicine. , 0, , .		0
1926	The emerging era of personalized medicine in advanced colorectal cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1411-1425.	1.4	6
1927	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
1928	Facts and Hopes in Immunotherapy of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4606-4617.	3.2	23
1929	Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 717-729.	1.0	4
1930	Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	0
1931	Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1932	Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 689-713.	1.3	1

#	ARTICLE	IF	CITATIONS
1933	Efficacy in randomised trials: the time matters. <i>Lancet Oncology</i> , The, 2022, 23, 839-840.	5.1	0
1934	Role of Angiopoietin-Tie axis in vascular and lymphatic systems and therapeutic interventions. <i>Pharmacological Research</i> , 2022, 182, 106331.	3.1	8
1935	The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. <i>Future Oncology</i> , 2022, 18, 2733-2744.	1.1	1
1936	Immunotherapy and targeted therapies for colorectal liver metastasis. , 2023, , 231-246.		0
1937	Pharmacokinetic study of deufrquintinibs in rats by HPLCâ€MS/MS after oral administration. <i>Biomedical Chromatography</i> , 0, , .	0.8	1
1938	Trends in Surgical Treatment for Liver Metastasis from Colorectal Cancer. <i>Journal of the Nihon University Medical Association</i> , 2022, 81, 127-132.	0.0	0
1939	Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study. <i>Oncology Research and Treatment</i> , 2022, 45, 576-587.	0.8	2
1940	New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. <i>Life</i> , 2022, 12, 1137.	1.1	2
1941	Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. <i>Cancers</i> , 2022, 14, 3718.	1.7	6
1942	Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer â€“ the MetAction precision medicine study. <i>Acta OncolÃ³gica</i> , 2022, 61, 955-962.	0.8	3
1943	Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer. <i>Eurasian Journal of Medicine</i> , 2022, 54, 229-234.	0.2	1
1944	Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era. <i>Biomedicines</i> , 2022, 10, 1927.	1.4	16
1945	Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211152.	0.4	0
1946	Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). , 2022, 10, e005332.		18
1947	Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. <i>Nature Medicine</i> , 2022, 28, 1612-1618.	15.2	80
1948	Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) â€“ A case series. <i>European Journal of Cancer</i> , 2022, 174, 37-39.	1.3	1
1949	Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). <i>ESMO Open</i> , 2022, 7, 100567.	2.0	9
1950	Identification of COX4I2 as a hypoxia-associated gene acting through FGF1 to promote EMT and angiogenesis in CRC. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, .	2.7	6



#	ARTICLE	IF	CITATIONS
1951	Role of dual anti-HER2 therapy before liver resection for rectal metastases. <i>Journal of Surgical Case Reports</i> , 2022, 2022, .	0.2	0
1952	Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. <i>Lancet Oncology</i> , 2022, 23, 1261-1273.	5.1	117
1953	Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. <i>Cancer Treatment Reviews</i> , 2022, 110, 102460.	3.4	14
1954	TIE2-high cervical cancer cells promote tumor angiogenesis by upregulating TIE2 and VEGFR2 in endothelial cells. <i>Translational Oncology</i> , 2022, 26, 101539.	1.7	3
1955	Systemic Treatments and Related Side Effects in Thyroid Cancer. , 2022, , 153-170.		0
1956	Therapy-Induced Toxicities Associated with the Onset of Cachexia. , 2022, , 139-153.		0
1957	Real-world experience of safety and effectiveness of regorafenib for treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma: a post-marketing surveillance study in Korea. <i>Journal of Cancer</i> , 2022, 13, 3396-3403.	1.2	3
1958	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1959	Substanzen gegen molekulare Zielstrukturen. <i>Springer Reference Medizin</i> , 2022, , 1-14.	0.0	0
1960	Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 880-880.	0.7	1
1961	Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3965-3976.	1.2	2
1962	Clinical trial design in the era of precision medicine. <i>Genome Medicine</i> , 2022, 14, .	3.6	68
1963	A Case Report of International Normalized Ratio Changes in Patients Taking Warfarin with Regorafenib. <i>Journal of Korean Society of Health-System Pharmacists</i> , 2022, 39, 368-374.	0.1	0
1964	Towards precision oncology with patient-derived xenografts. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 719-732.	12.5	33
1965	Value-based analysis of therapies in refractory metastatic colorectal cancer in US. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	0
1966	Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2022, 8, .	0.4	1
1967	Regorafenib for the Treatment of Sarcoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1477-1502.	1.3	3
1968	The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1969	Multicentre single-arm phase II trial evaluating the safety and efficacy of Panitumumab and irinotecan in NeoRAS Wild-type metastatic colorectal cancer patients (C-PROWESS trial): study protocol. <i>BMJ Open</i> , 2022, 12, e063071.	0.8	6
1970	A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). <i>Cancer Research Communications</i> , 2022, 2, 1188-1196.	0.7	4
1971	CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice. <i>Tumori</i> , 2023, 109, 387-393.	0.6	4
1972	A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1974	Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy: A real-world study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1977	Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study). <i>International Journal of Clinical Oncology</i> , 2022, 27, 1859-1866.	1.0	3
1978	Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	0
1979	Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/ $\beta$ -Catenin Signaling in BRAF-mutant Colorectal Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1777-1787.	1.9	3
1980	Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. <i>Cancer Treatment Reviews</i> , 2022, 110, 102466.	3.4	4
1981	Rapid, deep and long lasting response to cetuximab. <i>Onkologie (Czech Republic)</i> , 2022, 16, 222-225.	0.0	0
1982	The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. <i>Life</i> , 2022, 12, 1552.	1.1	0
1984	Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment. <i>Supportive Care in Cancer</i> , 2022, 30, 10203-10211.	1.0	2
1985	Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1986	Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
1987	Targeting Mitochondria and Oxidative Stress in Cancer- and Chemotherapy-Induced Muscle Wasting. <i>Antioxidants and Redox Signaling</i> , 0, , .	2.5	2
1988	Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?. <i>Journal of Neuro-Oncology</i> , 2022, 160, 389-402.	1.4	4
1989	PET-Uptake in Liver Metastases as Method to Predict Tumor Biological Behavior in Patients Transplanted for Colorectal Liver Metastases Developing Lung Recurrence. <i>Cancers</i> , 2022, 14, 5042.	1.7	2
1990	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59

#	ARTICLE	IF	CITATIONS
1991	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. <i>Cancers</i> , 2022, 14, 4828.	1.7	11
1992	Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2022, 17, 635-642.	1.7	2
1994	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
1996	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1997	Molecular mechanism of VEGF and its role in pathological angiogenesis. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1938-1965.	1.2	30
1998	Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer. <i>Oncotarget</i> , 2022, 13, 1140-1152.	0.8	1
1999	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 10-32.	0.6	316
2000	Eficácia e Segurança de Regorafenibe em Pacientes com Características de Bom Prognóstico no Tratamento do Câncer Colorretal Metastático: Análise de Subgrupo do Estudo CORRECT. <i>Revista Brasileira De Cancerologia</i> , 2022, 68, .	0.0	0
2002	CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial. <i>ESMO Open</i> , 2022, 7, 100594.	2.0	6
2003	A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). <i>European Journal of Cancer</i> , 2022, 177, 154-163.	1.3	4
2004	Regorafenib Adverse Drug Reactions among Patients in King Abdullah Medical City; A Chart Review Study. <i>International Journal of Pharmaceutical Research and Allied Sciences</i> , 2022, 11, 24-32.	0.1	0
2005	Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
2006	Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2007	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead? A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14117.	1.8	7
2008	Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer. <i>Cancer Medicine</i> , 0, .	1.3	1
2009	Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. <i>Journal of Clinical Oncology</i> , 2023, 41, 460-471.	0.8	16
2011	Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance. <i>Cells</i> , 2022, 11, 3663.	1.8	4
2012	Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials. <i>Oncologist</i> , 2023, 28, e36-e44.	1.9	0

#	ARTICLE	IF	CITATIONS
2013	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292.		0
2014	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. , 2022, , 153-172.		1
2015	A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. Neoplasia, 2023, 35, 100856.	2.3	4
2016	Regorafenib and trifluridine/tipiracil in real clinical practice. Journal of Cancer Research and Therapeutics, 2022, 18, 367.	0.3	2
2017	Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report. Frontiers in Oncology, 0, 12, .	1.3	1
2018	Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	1
2019	An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. Clinical Colorectal Cancer, 2023, 22, 76-84.	1.0	2
2020	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 7523.	1.0	1
2021	Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis. Cancer Research and Treatment, 2023, 55, 626-635.	1.3	5
2022	Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C. New England Journal of Medicine, 2023, 388, 44-54.	13.9	100
2023	Efficacy and Safety of TACE Combined with Regorafenib versus TACE in the Third-Line Treatment of Colorectal Liver Metastases. Journal of Oncology, 2022, 2022, 1-13.	0.6	1
2024	Characterization of Glioblastoma Cells Response to Regorafenib. Cancers, 2022, 14, 6193.	1.7	2
2025	Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer. BMC Geriatrics, 2022, 22, .	1.1	2
2026	A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open, 2022, 7, 100639.	2.0	21
2027	Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	0
2028	Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy. Acta Biomaterialia, 2023, 157, 500-510.	4.1	5
2029	Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. European Journal of Cancer, 2023, 181, 26-37.	1.3	6
2030	Current Targeted Therapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 1702.	1.8	22

#	ARTICLE	IF	CITATIONS
2031	Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib. <i>Journal of Cancer Research and Therapeutics</i> , 2022, .	0.3	0
2032	Clinical activity of regorafenib in elderly patients with recurrent glioblastoma. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	1
2033	TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients. <i>Tumori</i> , 0, , 030089162211479.	0.6	0
2034	Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 596.	1.0	0
2035	Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC Trial. <i>Digestion</i> , 2023, 104, 233-242.	1.2	0
2036	Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. <i>Cells</i> , 2023, 12, 258.	1.8	10
2037	Projecting overall survival in health-economic models: uncertainty and maturity of data. <i>Current Medical Research and Opinion</i> , 2023, 39, 367-374.	0.9	1
2038	Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102078.	0.7	1
2039	Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study. <i>ESMO Open</i> , 2023, 8, 100748.	2.0	0
2040	Psymberin, a marine-derived natural product, induces cancer cell growth arrest and protein translation inhibition. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
2041	New developments in targeted therapy for metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211485.	1.4	8
2042	Regorafenib-Induced Radiation Recall Presenting as Acute Blood Loss Anemia With Rectal Bleeding and Severe Proctitis. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2023, 11, 232470962311546.	0.3	1
2044	Regorafenib induces Bim-mediated intrinsic apoptosis by blocking AKT-mediated FOXO3a nuclear export. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	5
2045	A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311523.	0.8	4
2046	Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2023, 15, 863.	1.7	6
2047	Multiple immunosuppressants for immune-related acholia in a patient with metastatic colorectal cancer. <i>Journal of Cancer Research and Practice</i> , 2023, 10, 38.	0.2	0
2048	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. <i>World Journal of Gastroenterology</i> , 0, 29, 926-948.	1.4	4
2049	Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1

#	ARTICLE	IF	CITATIONS
2050	Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials. <i>Cancers</i> , 2023, 15, 2117.	1.7	4
2051	Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	2
2052	Guidance for Treating the Older Adults with Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 644-666.	1.3	0
2053	Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0
2054	Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2055	Long-term response of more than 9% years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2023, 34, 451-454.	0.7	2
2056	Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
2057	HER2 neu™ promise for mCRC. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 8, 3-8.	0.0	0
2058	Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
2059	Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
2060	Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review. <i>Cancers</i> , 2023, 15, 1135.	1.7	2
2061	Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice. <i>Medicina (Lithuania)</i> , 2023, 59, 350.	0.8	3
2062	Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review. <i>World Journal of Clinical Oncology</i> , 0, 14, 81-88.	0.9	2
2063	Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2064	Metastatic colorectal cancer: mechanisms and emerging therapeutics. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 222-236.	4.0	30
2065	Pembrolizumab for previously treated, microsatellite instability“high/mismatch repair“deficient advanced colorectal cancer: final analysis of KEYNOTE-164. <i>European Journal of Cancer</i> , 2023, 186, 185-195.	1.3	13
2066	Effectiveness, safety, and prognostic factors of trifluridine/tipiracil for the treatment of patients with metastatic colorectal cancer in routine clinical practice. <i>Journal of Gastrointestinal Oncology</i> , 2023, .	0.6	0
2067	Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. <i>Cancers</i> , 2023, 15, 1473.	1.7	1

#	ARTICLE	IF	CITATIONS
2068	Antitumor Therapy Targeting the Tumor Microenvironment. <i>Journal of Oncology</i> , 2023, 2023, 1-16.	0.6	4
2069	Stage IV Colorectal Cancer Management and Treatment. <i>Journal of Clinical Medicine</i> , 2023, 12, 2072.	1.0	18
2070	Liver transplantation in metastatic colorectal cancer: are we ready for it?. <i>British Journal of Cancer</i> , 2023, 128, 1797-1806.	2.9	5
2071	Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2023, 55, 927-938.	1.3	4
2072	Cetuximab as thirdâ€line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma <i>RAS/BRAF</i> wildâ€type circulating tumor <scp>DNA</scp>: Individual patient data pooled analysis of <scp>CRICKET</scp> and <scp>CAVE</scp> trials. <i>Cancer Medicine</i> , 2023, 12, 9392-9400.	1.3	3
2073	Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. <i>World Journal of Gastroenterology</i> , 0, 29, 1395-1426.	1.4	8
2074	The Network Zoo: a multilingual package for the inference and analysis of gene regulatory networks. <i>Genome Biology</i> , 2023, 24, .	3.8	4
2075	Targeted therapies for the treatment of soft tissue sarcoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
2076	The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. <i>European Journal of Pharmacology</i> , 2023, 949, 175586.	1.7	27
2077	Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy. <i>JAMA Oncology</i> , 2023, 9, 627.	3.4	15
2078	Immunotherapy Success for Microsatellite Stable Colorectal Cancersâ€Searching for the Horizon. <i>JAMA Oncology</i> , 2023, 9, 615.	3.4	0
2079	Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. <i>Cancers</i> , 2023, 15, 1679.	1.7	6
2080	Insights on the Association between Thyroid Diseases and Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2234.	1.0	2
2081	Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. <i>Cancers</i> , 2023, 15, 1766.	1.7	6
2082	Integration of Human and Viral miRNAs in Epstein-Barr Virus-Associated Tumors and Implications for Drug Repurposing. <i>OMICS A Journal of Integrative Biology</i> , 2023, 27, 93-108.	1.0	0
2083	Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, , .	0.4	0
2084	Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer. <i>Cancer Management and Research</i> , 0, Volume 15, 277-289.	0.9	0
2085	Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5840.	1.8	1

#	ARTICLE	IF	CITATIONS
2086	Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2023, , 101477.	0.5	0
2087	Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 1911-1941.	1.4	0
2088	Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. <i>EClinicalMedicine</i> , 2023, 58, 101917.	3.2	12
2089	A method with safety and convenience to synthesize Regorafenib. , 0, 40, 271-276.		0
2090	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.		0
2091	Targeting angiogenesis in oncology, ophthalmology and beyond. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 476-495.	21.5	43
2092	Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	3
2093	Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 710-726.	2.5	2
2094	Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 495-519.	0.8	12
2100	A review on emerging targeted therapies for the management of metastatic colorectal cancers. , 2023, 40, .		6
2110	Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID. <i>Archives of Microbiology</i> , 2023, 205, .	1.0	2
2113	Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2119	Targeted Therapy and Personalized Medicine. <i>Cancer Treatment and Research</i> , 2023, , 177-205.	0.2	2
2139	Angiogenic signaling pathways and anti-angiogenic therapy for cancer. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	68
2149	Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
2159	A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative. <i>Nature Medicine</i> , 2023, 29, 2389-2390.	15.2	2
2171	Recent Advancements in the Inhibition of Metastasis of Colorectal Cancer Using Anticancer Compounds. , 2023, , 1-32.		0
2210	New options for late-line treatment of metastatic colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 0, , .	8.2	0



#	ARTICLE	IF	CITATIONS
2214	Editorial: Molecular targets for the treatment of metastatic colorectal cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0